ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer

A Randomized, Open-label Study of the Effect of First-line Herceptin in Combination With a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients With HER2-positive Advanced Gastric Cancer

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01041404

Enrollment

584

Registered

2009-12-31

Start date

2005-09-30

Completion date

2010-06-30

Last updated

2014-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Brief summary

This parallel, randomized, open-label, multi-centre study will evaluate the effect on overall survival of trastuzumab (Herceptin) in combination with a chemotherapy compared to the chemotherapy alone in patients with HER2-positive advanced gastric cancer. Trastuzumab (Herceptin) will be administered as intravenous infusion of 6 mg/kg (loading dose 8 mg/kg) every 3 weeks. The chemotherapy consists of a combination of 6 cycles of fluorouracil (800 mg/m2/day intravenous infusion every 3 weeks) and cisplatin (80 mg/m2 intravenous infusion every 3 weeks), or capecitabine (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks) and cisplatin (80 mg/m2 intravenous infusion every 3 weeks). Treatment with trastuzumab (Herceptin) will continue until disease progression. The target sample size is 300-600 patients.

Interventions

DRUGTrastuzumab

Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression

DRUGFluorouracil

800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles

DRUGCisplatin

80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles

DRUGCapecitabine

1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients \>=18 years of age * Inoperable locally advanced, recurrent, and/or metastatic cancer of the stomach or gastro-esophageal junction * Adenocarcinoma * HER2-positive tumors

Exclusion criteria

* Previous chemotherapy for advanced/metastatic disease * Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome * History of cardiac disease * Dyspnoea at rest, due to complications of advanced malignancy or other disease, or patients who require supportive oxygen therapy

Design outcomes

Primary

Measure	Time frame	Description
Overall Survival (OS) - Percentage of Participants With an Event	Baseline (BL), Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.
Overall Survival - Time to Event	BL, Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	The median time, in months, from the date of randomization to the date of an OS event. Participants were censored at the last date tumor measurement, the last date in the study drug log, or the date of last follow-up.

Secondary

Measure	Time frame	Description
Time to Progression (TTP) - Percentage of Participants With an Event	BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	TTP was defined as the time from the date of randomization and the date of the first occurrence of PD. Participants were censored at the last date of tumor assessment, the last date in the study drug log, or the last date of follow-up.
Time to Progression - Time to Event	BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	The median time, in months, from the date of randomized to the date of a TTP event. Participants were censored at the last date of tumor assessment, the last date in the study drug log, or the last date of follow-up.
Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors (RECIST)	BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels.
Duration of Response - Percentage of Participants With an Event	BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	Duration of response was defined for responders as the time from the date on which the CR or PR was first recorded to the date on which PD is first noted. Participants were censored on the date of death, the date of last tumor measurement, the last date in study drug log, or the date of last follow-up.
Duration of Response	BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	The median time, in months, of the duration of response. Participants were censored at the date of death, the date of last tumor measurement, the last date in study drug log, or the date of last follow-up.
Percentage of Participants With Clinical Benefit	BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	Clinical benefit was defined as stable disease (SD), CR, or PR for 6 weeks or longer as determined by RECIST. For TLs, SD was defined as neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD, taking as a reference the smallest SLD recorded since treatment had started. For NTLs, SD was defined as a persistence of one or more NTLs and/or maintenance of tumor marker levels above the normal limits.
European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score equals (=) better level of functioning or greater degree of symptoms.
Progression-Free Survival (PFS) - Percentage of Participants With an Event	BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	PFS was defined as the time from the date of randomization to the date of the first documentation of progressive disease (PD) or date of death, whichever occurs first. For target lesions (TL), PD was defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD) of TLs, taking as a reference the smallest SLD recorded since the treatment started, or the appearance of one or more lesions. For non-target lesions (NTL), PD was defined as an unequivocal progression of existing NTLs. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.
Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	The participant assessed their pain on a 0 to 100 millimeter (mm) horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as no pain and the right-hand extreme equals 100 mm as unbearable pain. A negative change indicated improvement.
Percentage of Participants With a Change in Analgesic Medication During the Study	BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	Analgesic medications were recorded throughout the study until disease progression.
Body Weight (Kilograms [kg]) at BL	BL	—
Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight	BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	Change in body weight was categorized as an increase of greater than (\>)5 percent (%), no change (plus or minus \[±\]5%), decrease of \>5-10%, or a decrease of \>10% from BL to the end of study. Time windows were applied in order to assign visits to weight measurements, and the lowest post-screening value recorded was used for the analysis. The percentage change in weight from screening was summarized over time.
Steady State Trastuzumab Area Under the Concentration (AUC)	Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106	Individual steady state predicted exposure, as assessed by median AUC (measured as mg multiplied by \[\*\] day per liter \[L\]) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion. Individual steady state AUC was calculated using all available PK samples from all timepoints.
Trastuzumab Minimum Serum Concentration (Cmin)	Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106	Median Cmin (measured as milligrams per liter \[mg/L\]) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion.
Trastuzumab Maximum Serum Concentration (Cmax)	Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106	Median Cmax (measured as mg/L) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion.
EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	The QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms.
Progression-Free Survival - Time to Event	BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis	The median time, in months, from the date of randomization to the date of a PFS event. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.

Countries

Australia, Belgium, Brazil, China, Costa Rica, Denmark, Finland, France, Germany, Guatemala, India, Italy, Japan, Mexico, Panama, Peru, Portugal, Russia, South Africa, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom

Participant flow

Participants by arm

Arm	Count
Fluoropyrimidine/Cisplatin (FP) Participants received fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles as follows: cisplatin 80 mg/m\^2, IV, on Day 1 and EITHER: 5-FU 800 mg/m\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\^2, tablets, PO, BID from the evening of Day 1 through the morning of Day 15.	290
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) Participants received trastuzumab plus fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles (except as noted) as follows: trastuzumab 8 mg/kg, IV, on Day 1 (Cycle 1), followed by 6 mg/kg, IV (Cycles 2 onward, administered until disease progression); cisplatin 80 mg/m\^2 IV on Day 1; and EITHER 5-FU 800 mg/m\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\^2 tablets, PO BID from the evening of Day 1 through the morning of Day 15.	294
Total	584

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Adverse Event	45	35
Overall Study	Failure to Return	1	2
Overall Study	Lack of Efficacy	200	210
Overall Study	Other	11	23
Overall Study	Protocol Violation	4	0
Overall Study	Violation of Selection Criteria	0	1
Overall Study	Withdrawal by Subject	29	23

Baseline characteristics

Characteristic	Fluoropyrimidine/Cisplatin (FP)	Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Total
Age, Continuous	58.5 years STANDARD_DEVIATION 11.22	59.4 years STANDARD_DEVIATION 10.75	59.0 years STANDARD_DEVIATION 10.99
Sex: Female, Male Female	72 Participants	68 Participants	140 Participants
Sex: Female, Male Male	218 Participants	226 Participants	444 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	— / —	— / —
other Total, other adverse events	279 / 290	286 / 294
serious Total, serious adverse events	81 / 290	106 / 294

Outcome results

Primary

Overall Survival (OS) - Percentage of Participants With an Event

OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.

Time frame: Baseline (BL), Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS

Arm	Measure	Value (NUMBER)
Fluoropyrimidine/Cisplatin (FP)	Overall Survival (OS) - Percentage of Participants With an Event	62.8 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Overall Survival (OS) - Percentage of Participants With an Event	56.8 percentage of participants

Primary

Overall Survival - Time to Event

The median time, in months, from the date of randomization to the date of an OS event. Participants were censored at the last date tumor measurement, the last date in the study drug log, or the date of last follow-up.

Time frame: BL, Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS

Arm	Measure	Value (MEDIAN)
Fluoropyrimidine/Cisplatin (FP)	Overall Survival - Time to Event	11.1 months
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Overall Survival - Time to Event	13.8 months

p-value: 0.004695% CI: [0.6, 0.91]Log Rank

Secondary

Body Weight (Kilograms [kg]) at BL

Time frame: BL

Population: FAS

Arm	Measure	Value (MEDIAN)
Fluoropyrimidine/Cisplatin (FP)	Body Weight (Kilograms [kg]) at BL	60 kg
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Body Weight (Kilograms [kg]) at BL	61 kg

Secondary

Duration of Response

The median time, in months, of the duration of response. Participants were censored at the date of death, the date of last tumor measurement, the last date in study drug log, or the date of last follow-up.

Time frame: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS; only participants with a CR or PR were included in the analysis.

Arm	Measure	Value (MEDIAN)
Fluoropyrimidine/Cisplatin (FP)	Duration of Response	4.8 months
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Duration of Response	6.9 months

p-value: <0.000195% CI: [0.4, 0.73]Log Rank

Secondary

Duration of Response - Percentage of Participants With an Event

Duration of response was defined for responders as the time from the date on which the CR or PR was first recorded to the date on which PD is first noted. Participants were censored on the date of death, the date of last tumor measurement, the last date in study drug log, or the date of last follow-up.

Time frame: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS; only participants with a CR or PR were included in the analysis.

Arm	Measure	Value (NUMBER)
Fluoropyrimidine/Cisplatin (FP)	Duration of Response - Percentage of Participants With an Event	80.0 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Duration of Response - Percentage of Participants With an Event	71.9 percentage of participants

Secondary

EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores

The QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms.

Time frame: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS; n = number of participants assessed for a specific parameter at a given visit.

Arm	Measure	Group	Value (MEAN)	Dispersion
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 52 (n=8,30)	12.5 scores on a scale	Standard Error 6.1
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 10 (n=176,203)	8.5 scores on a scale	Standard Error 0.97
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 19 (n=114,143)	9.5 scores on a scale	Standard Error 1.52
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 22 (n=79,143)	10.0 scores on a scale	Standard Error 2.11
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 28 (n=47,111)	6.6 scores on a scale	Standard Error 1.84
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Final Visit (n=157,159	15.4 scores on a scale	Standard Error 1.77
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: BL (n=276,287)	29.7 scores on a scale	Standard Error 1.32
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 4 (n=234,250)	21.6 scores on a scale	Standard Error 1.15
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 7 (n=181,219)	19.4 scores on a scale	Standard Error 1.26
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 10 (n=176,203)	17.0 scores on a scale	Standard Error 1.11
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 13 (n=152,183)	16.0 scores on a scale	Standard Error 1.25
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 22 (n=79,143)	15.8 scores on a scale	Standard Error 2.05
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 25 (n=64,124)	11.3 scores on a scale	Standard Error 1.82
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 28 (n=47,111)	11.2 scores on a scale	Standard Error 1.95
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 31 (n=45,95)	12.6 scores on a scale	Standard Error 2.33
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 34 (n=37,87)	12.2 scores on a scale	Standard Error 2.18
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 37 (n=29,64)	13.8 scores on a scale	Standard Error 2.9
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 43 (n=12,43)	13.0 scores on a scale	Standard Error 3.41
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 55 (n=6,24)	9.7 scores on a scale	Standard Error 5.01
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 58 (n=6,21)	5.6 scores on a scale	Standard Error 4.12
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 61 (n=4,17)	4.2 scores on a scale	Standard Error 2.41
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 64 (n=3,20)	2.8 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 76 (n=3,8)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 79 (n=3,9)	2.8 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 91 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: BL (n=275,287)	18.3 scores on a scale	Standard Error 1.29
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 16 (n=120,165)	12.0 scores on a scale	Standard Error 1.55
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 19 (n=114,165)	11.3 scores on a scale	Standard Error 1.76
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 25 (n=64,124)	5.6 scores on a scale	Standard Error 1.21
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 31 (n=45,95)	7.4 scores on a scale	Standard Error 1.69
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 34 (n=45,95)	7.2 scores on a scale	Standard Error 2.16
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 37 (n=29,64)	6.1 scores on a scale	Standard Error 1.62
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 40 (n=24,55)	7.9 scores on a scale	Standard Error 2.8
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 49 (n=10,36)	2.2 scores on a scale	Standard Error 1.48
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 52 (n=8,30)	2.8 scores on a scale	Standard Error 1.82
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 58 (n=6,21)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 61 (n=4,17)	2.8 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 64 (n=3,20)	3.7 scores on a scale	Standard Error 3.7
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 67 (n=4,16)	2.8 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 76 (n=3,8)	3.7 scores on a scale	Standard Error 3.7
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Eating Restrictions (ER) Scale: BL (n=276,287)	27.4 scores on a scale	Standard Error 1.44
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 19 (n=114,143)	20.8 scores on a scale	Standard Error 2.01
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 22 (n=79,143)	15.5 scores on a scale	Standard Error 2.14
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 40 (n=24,55)	13.5 scores on a scale	Standard Error 3.32
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 31 (n=45,95)	13.4 scores on a scale	Standard Error 2.69
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 49 (n=10,36)	11.7 scores on a scale	Standard Error 3.09
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 55 (n=6,24)	8.3 scores on a scale	Standard Error 4.3
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 61 (n=4,17)	4.2 scores on a scale	Standard Error 2.41
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 64 (n=3,20)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 85 (n=2,6)	4.2 scores on a scale	Standard Error 4.17
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 91 (n=2,4)	8.3 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Final Visit (n=157,160)	23.8 scores on a scale	Standard Error 1.85
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 13 (n=152,183)	35.7 scores on a scale	Standard Error 2.01
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 19 (n=114,143)	35.8 scores on a scale	Standard Error 2.4
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 25 (n=64,124)	25.2 scores on a scale	Standard Error 2.86
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 28 (n=47,111)	27.4 scores on a scale	Standard Error 3.65
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 37 (n=29,64)	27.2 scores on a scale	Standard Error 4.79
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 46 (n=14,42)	26.2 scores on a scale	Standard Error 6.34
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 52 (n=8,30)	23.6 scores on a scale	Standard Error 7.98
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 61 (n=4,17)	8.3 scores on a scale	Standard Error 5.32
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 79 (n=3,9)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 91 (n=2,4)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 145 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: BL (n=274,287)	24.5 scores on a scale	Standard Error 1.7
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 4 (n=232,249)	24.0 scores on a scale	Standard Error 1.81
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 16 (n=120,165)	23.9 scores on a scale	Standard Error 2.41
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 22 (n=79,143)	19.0 scores on a scale	Standard Error 2.92
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 25 (n=64,124)	16.1 scores on a scale	Standard Error 3.06
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 31 (n=45,95)	12.6 scores on a scale	Standard Error 3.23
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 37 (n=29,64)	12.6 scores on a scale	Standard Error 4.19
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 40 (n=23,55)	8.7 scores on a scale	Standard Error 3.76
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 46 (n=14,42)	9.5 scores on a scale	Standard Error 4.18
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 49 (n=10,36)	16.7 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 55 (n=6,24)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 61 (n=4,17)	8.3 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 70 (n=3,14)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 67 (n=4,16)	8.3 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 76 (n=3,8)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 85 (n=2,6)	16.7 scores on a scale	Standard Error 16.67
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Final Visit (n=157,157)	24.0 scores on a scale	Standard Error 2.52
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: BL (n=275,286)	17.2 scores on a scale	Standard Error 1.56
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 4 (n=234,249)	20.7 scores on a scale	Standard Error 1.63
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 7 (n=179,217)	20.1 scores on a scale	Standard Error 1.78
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 10 (n=176,200)	21.8 scores on a scale	Standard Error 1.86
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 13 (n=151,181)	19.9 scores on a scale	Standard Error 2.08
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 16 (n=119,165)	20.4 scores on a scale	Standard Error 2.22
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 19 (n=113,143)	24.5 scores on a scale	Standard Error 2.37
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 22 (n=79,143)	19.0 scores on a scale	Standard Error 2.86
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 25 (n=64,124)	10.9 scores on a scale	Standard Error 2.23
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 28 (n=47,111)	12.1 scores on a scale	Standard Error 2.76
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 31 (n=45,95)	8.1 scores on a scale	Standard Error 2.63
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 34 (n=37,87)	6.3 scores on a scale	Standard Error 2.53
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 46 (n=14,42)	4.8 scores on a scale	Standard Error 3.24
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 49 (n=9,36)	7.4 scores on a scale	Standard Error 4.9
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 52 (n=8,30)	4.2 scores on a scale	Standard Error 4.17
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 55 (n=6,24)	11.1 scores on a scale	Standard Error 7.03
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 58 (n=6,21)	11.1 scores on a scale	Standard Error 7.03
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 61 (n=4,17)	8.3 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 64 (n=3,20)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 67 (n=4,16)	8.3 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 76 (n=3,8)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 85 (n=2, 6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Final Visit (n=157,158)	25.3 scores on a scale	Standard Error 2.26
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: BL (n=272,286)	30.9 scores on a scale	Standard Error 1.95
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 4 (n=233,249)	32.6 scores on a scale	Standard Error 2.1
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 16 (n=119,165)	29.1 scores on a scale	Standard Error 2.69
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 19 (n=114,140)	30.7 scores on a scale	Standard Error 2.82
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 25 (n=64,124)	22.4 scores on a scale	Standard Error 3.32
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 28 (n=47,111)	23.4 scores on a scale	Standard Error 4.41
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 34 (n=37,87)	18.9 scores on a scale	Standard Error 4.75
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 40 (n=24,55)	20.8 scores on a scale	Standard Error 5.96
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 43 (n=12,43)	27.8 scores on a scale	Standard Error 6.91
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 49 (n=10,36)	16.7 scores on a scale	Standard Error 7.45
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 52 (n=8,30)	16.7 scores on a scale	Standard Error 8.91
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 55 (n=6,24)	16.7 scores on a scale	Standard Error 11.39
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 61 (n=4,17)	8.3 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 67 (n=4,16)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 70 (n=4,14)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 73 (n=3,12)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 52 (n=3,4)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 58 (n=2,3)	16.7 scores on a scale	Standard Error 16.67
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 64 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 82 (n=1,1)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 85 (n=1,1)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 91 (n=1,1)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 106 (n=1,1)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 130 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Final Visit (n=61,60)	23.0 scores on a scale	Standard Error 3.62
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: BL (n=276,287)	47.5 scores on a scale	Standard Error 1.66
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 4 (n=234,250)	42.0 scores on a scale	Standard Error 1.66
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 7 (n=181,220)	40.6 scores on a scale	Standard Error 1.77
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 10 (n=176,203)	38.2 scores on a scale	Standard Error 1.98
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 16 (n=120,165)	32.9 scores on a scale	Standard Error 2.27
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 22 (n=79,143)	31.7 scores on a scale	Standard Error 3.16
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 31 (n=45,95)	29.1 scores on a scale	Standard Error 4.36
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 34 (n=37,87)	23.1 scores on a scale	Standard Error 3.69
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 40 (n=24,55)	29.6 scores on a scale	Standard Error 3.99
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 43 (n=12,43)	30.6 scores on a scale	Standard Error 7.63
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 49 (n=14,42)	20.0 scores on a scale	Standard Error 7.55
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 55 (n=6,24)	31.5 scores on a scale	Standard Error 12.31
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 58 (n=6,21)	20.4 scores on a scale	Standard Error 10.11
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 64 (n=3,20)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 67 (n=4,16)	11.1 scores on a scale	Standard Error 6.42
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 70 (n=3,14)	3.7 scores on a scale	Standard Error 3.7
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 73 (n=3,12)	7.4 scores on a scale	Standard Error 7.41
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 76 (n=3,8)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 82 (n=2,6)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 85 (n=2,6)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 88 (n=2,6)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 94 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Final Visit (n=157,160)	41.5 scores on a scale	Standard Error 2.19
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 7 (n=180,219)	24.6 scores on a scale	Standard Error 2.02
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 10 (n=176,203)	23.5 scores on a scale	Standard Error 1.85
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 13 (n=152,183)	23.2 scores on a scale	Standard Error 2.06
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 19 (n=113,143)	22.4 scores on a scale	Standard Error 2.56
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 28 (n=47,111)	10.6 scores on a scale	Standard Error 2.51
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 34 (n=37,87)	9.9 scores on a scale	Standard Error 3.38
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 43 (n=12,43)	11.1 scores on a scale	Standard Error 4.74
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 58 (n=6,21)	11.1 scores on a scale	Standard Error 7.03
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 64 (n=3,20)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 73 (n=3,12)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: BL (n=276,287)	18.7 scores on a scale	Standard Error 1.27
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 4 (n=234,250)	11.8 scores on a scale	Standard Error 0.92
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 7 (n=181,220)	10.9 scores on a scale	Standard Error 1.16
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 13 (n=152,183)	8.8 scores on a scale	Standard Error 1.15
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 16 (n=120,165)	10.2 scores on a scale	Standard Error 1.5
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 25 (n=64,124)	6.9 scores on a scale	Standard Error 1.99
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 31 (n=45,95)	6.4 scores on a scale	Standard Error 2.16
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 34 (n=37,87)	3.9 scores on a scale	Standard Error 1.44
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 37 (n=29,64)	5.4 scores on a scale	Standard Error 2.04
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 40 (n=24,55)	3.7 scores on a scale	Standard Error 1.59
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 43 (n=12,43)	4.6 scores on a scale	Standard Error 2.89
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 46 (n=14,42)	2.4 scores on a scale	Standard Error 1.26
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 49 (n=10,36)	4.4 scores on a scale	Standard Error 2.46
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 52 (n=8,30)	1.4 scores on a scale	Standard Error 1.39
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 55 (n=6,24)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 58 (n=6,21)	3.7 scores on a scale	Standard Error 2.34
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 61 (n=4,17)	2.8 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 64 (n=3,20)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 67 (n=4,16)	2.8 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 70 (n=3,14)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 73 (n=3,12)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 76 (n=3,8)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 16 (n=120,165)	17.0 scores on a scale	Standard Error 1.45
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 19 (n=114,143)	19.2 scores on a scale	Standard Error 1.95
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 40 (n=24,55)	14.9 scores on a scale	Standard Error 2.97
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 46 (n=14,42)	15.5 scores on a scale	Standard Error 3.13
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 49 (n=10,36)	11.7 scores on a scale	Standard Error 4.51
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 52 (n=8,30)	9.4 scores on a scale	Standard Error 4
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 67 (n=4,16)	4.2 scores on a scale	Standard Error 4.17
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 70 (n=3,14)	2.8 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 73 (n=3,12)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 85 (n=2,6)	4.2 scores on a scale	Standard Error 4.17
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 88 (n=2,6)	8.3 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Final Visit (n=157,160)	24.7 scores on a scale	Standard Error 1.6
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 4 (n=234,250)	14.8 scores on a scale	Standard Error 1.14
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 7 (n=180,220)	12.8 scores on a scale	Standard Error 1.26
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 10 (n=176,203)	12.6 scores on a scale	Standard Error 1.29
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 13 (n=152,182)	12.8 scores on a scale	Standard Error 1.39
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 22 (n=79,143)	9.0 scores on a scale	Standard Error 1.79
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 28 (n=47,111)	6.6 scores on a scale	Standard Error 1.61
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 43 (n=12,42)	7.4 scores on a scale	Standard Error 3.44
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 46 (n=14,42)	4.8 scores on a scale	Standard Error 1.53
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 55 (n=6,24)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 70 (n=3,13)	3.7 scores on a scale	Standard Error 3.7
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 73 (n=3,12)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 58 (n=6,21)	11.1 scores on a scale	Standard Error 7.03
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Final Visit (n=1,5)	15.3 scores on a scale	Standard Error 1.48
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 4 (n=234,250)	20.6 scores on a scale	Standard Error 1.24
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 7 (n=181,220)	18.8 scores on a scale	Standard Error 1.36
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 10 (n=176,203)	17.5 scores on a scale	Standard Error 1.25
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 13 (n=152,183)	16.0 scores on a scale	Standard Error 1.77
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 16 (n=120,165)	17.8 scores on a scale	Standard Error 1.77
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 25 (n=64,124)	11.6 scores on a scale	Standard Error 2.14
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 28 (n=47,111)	13.9 scores on a scale	Standard Error 2.64
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 34 (n=37,87)	10.6 scores on a scale	Standard Error 2.16
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 37 (n=29,64)	12.5 scores on a scale	Standard Error 3.1
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 43 (n=12,43)	9.7 scores on a scale	Standard Error 3.22
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 46 (n=14,42)	10.9 scores on a scale	Standard Error 3.07
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 52 (n=8,30)	5.2 scores on a scale	Standard Error 2.19
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 58 (n=6,21)	9.7 scores on a scale	Standard Error 5.45
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 67 (n=4,16)	8.3 scores on a scale	Standard Error 4.81
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 70 (n=3,14)	2.8 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 73 (n=3,12)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 76 (n=3,8)	2.8 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 79 (n=3,9)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 82 (n=2,6)	4.2 scores on a scale	Standard Error 4.17
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 88 (n=2,6)	4.2 scores on a scale	Standard Error 4.17
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 64 (n=3,20)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 76 (n=3,8)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 88 (n=2,5)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Final Visit (n=157,159)	31.0 scores on a scale	Standard Error 2.58
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: BL (n=64,76)	15.1 scores on a scale	Standard Error 3.31
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 4 (n=68,71)	20.1 scores on a scale	Standard Error 3.43
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 7 (n=65,82)	25.1 scores on a scale	Standard Error 3.27
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 10 (n=75,78)	21.8 scores on a scale	Standard Error 3.07
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 13 (n=66,80)	22.2 scores on a scale	Standard Error 3.4
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 16 (n=53,72)	28.3 scores on a scale	Standard Error 4.34
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 19 (n=50,56)	23.3 scores on a scale	Standard Error 4.29
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 22 (n=38,54)	20.2 scores on a scale	Standard Error 4.45
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 25 (n=24,49)	13.9 scores on a scale	Standard Error 4.88
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 28 (n=20,39)	26.7 scores on a scale	Standard Error 7.87
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 31 (n=17,26)	15.7 scores on a scale	Standard Error 7.07
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 34 (n=13,24)	7.7 scores on a scale	Standard Error 5.54
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 37 (n=12,16)	8.3 scores on a scale	Standard Error 5.98
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 40 (n=11,13)	12.1 scores on a scale	Standard Error 6.78
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 43 (n=5,9)	6.7 scores on a scale	Standard Error 6.67
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 46 (n=5,13)	26.7 scores on a scale	Standard Error 19.44
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 49 (n=4,7)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 55 (n=2,6)	16.7 scores on a scale	Standard Error 16.67
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 61 (n=1,2)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 67 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 70 (n=1,2)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 73 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 76 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 79 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 88 (n=1,2)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 94 (n=1,2)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 97 (n=1,2)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 100 (n=1,2)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 103 (n=1,1)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 109 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 112 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 115 (n=1,2)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 118 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 121 (n=1,2)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 124 (n=1,2)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 127 (n=1,1)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 133 (n=1,1)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 37 (n=28,64)	8.3 scores on a scale	Standard Error 3.26
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 40 (n=24,55)	8.3 scores on a scale	Standard Error 3.01
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 43 (n=12,43)	5.6 scores on a scale	Standard Error 3.75
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 70 (n=3,14)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 73 (n=3,12)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 7 (n=180,219)	30.7 scores on a scale	Standard Error 2.19
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 10 (n=175,203)	30.1 scores on a scale	Standard Error 2.27
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 13 (n=152,182)	28.9 scores on a scale	Standard Error 2.54
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 22 (n=79,143)	28.7 scores on a scale	Standard Error 3.59
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 31 (n=45,95)	25.2 scores on a scale	Standard Error 4.87
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 37 (n=29,64)	23.0 scores on a scale	Standard Error 5.99
Fluoropyrimidine/Cisplatin (FP)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 46 (n=14,42)	21.4 scores on a scale	Standard Error 6.64
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 16 (n=53,72)	23.6 scores on a scale	Standard Error 3.26
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 88 (n=2,6)	14.8 scores on a scale	Standard Error 5.49
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 142 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 94 (n=2,6)	22.2 scores on a scale	Standard Error 2.87
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 118 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 76 (n=3,8)	2.8 scores on a scale	Standard Error 1.82
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 37 (n=29,64)	7.3 scores on a scale	Standard Error 2.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 97 (n=1,5)	31.1 scores on a scale	Standard Error 5.44
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 79 (n=3,9)	2.5 scores on a scale	Standard Error 1.63
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Final Visit (n=1,5)	18.3 scores on a scale	Standard Error 1.72
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 82 (n=2,6)	3.7 scores on a scale	Standard Error 2.34
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 88 (n=2,6)	1.9 scores on a scale	Standard Error 1.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Eating Restrictions (ER) Scale: BL (n=276,287)	23.9 scores on a scale	Standard Error 1.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 103 (n=1,4)	22.2 scores on a scale	Standard Error 4.54
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 109 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 19 (n=50,56)	21.4 scores on a scale	Standard Error 3.55
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 115 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 124 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 4 (n=234,250)	21.1 scores on a scale	Standard Error 1.19
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 112 (n=1,5)	22.2 scores on a scale	Standard Error 4.97
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 136 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 142 (n=0,2)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 115 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 115 (n=1,4)	19.4 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Final Visit (n=157,159	17.0 scores on a scale	Standard Error 1.92
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 7 (n=181,220)	19.0 scores on a scale	Standard Error 1.26
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 118 (n=1,5)	20.0 scores on a scale	Standard Error 6.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 4 (n=234,250)	21.8 scores on a scale	Standard Error 1.05
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 22 (n=38,54)	22.2 scores on a scale	Standard Error 3.52
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 121 (n=1,5)	15.6 scores on a scale	Standard Error 7.54
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 10 (n=176,203)	17.4 scores on a scale	Standard Error 1.23
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 13 (n=152,183)	16.2 scores on a scale	Standard Error 1.21
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 16 (n=120,165)	15.9 scores on a scale	Standard Error 1.23
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 130 (n=0,3)	18.5 scores on a scale	Standard Error 9.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 22 (n=79,143)	15.1 scores on a scale	Standard Error 1.58
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 121 (n=1,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 25 (n=64,124)	14.4 scores on a scale	Standard Error 1.63
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 133 (n=1,3)	18.5 scores on a scale	Standard Error 9.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 13 (n=152,183)	17.0 scores on a scale	Standard Error 1.34
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 31 (n=45,95)	14.6 scores on a scale	Standard Error 2.09
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 139 (n=0,2)	11.1 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 16 (n=120,165)	15.1 scores on a scale	Standard Error 1.4
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 37 (n=29,64)	13.8 scores on a scale	Standard Error 2.63
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 142 (n=0,2)	16.7 scores on a scale	Standard Error 16.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 46 (n=14,42)	10.1 scores on a scale	Standard Error 2.35
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 145 (n=0,2)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 55 (n=6,24)	4.5 scores on a scale	Standard Error 1.42
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 22 (n=79,143)	13.6 scores on a scale	Standard Error 1.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: BL (n=274,287)	23.9 scores on a scale	Standard Error 1.7
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 61 (n=4,17)	5.4 scores on a scale	Standard Error 2.36
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 4 (n=232,249)	23.3 scores on a scale	Standard Error 1.59
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 64 (n=3,20)	9.6 scores on a scale	Standard Error 2.28
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 70 (n=3,14)	6.5 scores on a scale	Standard Error 2.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 73 (n=3,12)	9.7 scores on a scale	Standard Error 3.95
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 28 (n=20,39)	14.5 scores on a scale	Standard Error 4.38
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 7 (n=180,219)	26.9 scores on a scale	Standard Error 1.87
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 79 (n=3,9)	7.4 scores on a scale	Standard Error 3.79
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 25 (n=64,124)	12.9 scores on a scale	Standard Error 1.39
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 91 (n=2,6)	2.1 scores on a scale	Standard Error 2.08
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 97 (n=1,5)	8.3 scores on a scale	Standard Error 3.73
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 103 (n=1,4)	8.3 scores on a scale	Standard Error 3.4
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 106 (n=1,4)	6.3 scores on a scale	Standard Error 3.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 10 (n=176,203)	25.0 scores on a scale	Standard Error 1.96
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 112 (n=1,5)	10.0 scores on a scale	Standard Error 4.86
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 124 (n=1,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 115 (n=1,4)	4.2 scores on a scale	Standard Error 2.41
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 13 (n=152,183)	21.1 scores on a scale	Standard Error 1.95
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 28 (n=47,111)	11.3 scores on a scale	Standard Error 1.37
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 127 (n=1,3)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 19 (n=113,143)	20.5 scores on a scale	Standard Error 2.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 130 (n=0,3)	11.1 scores on a scale	Standard Error 7.35
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 133 (n=1,3)	13.9 scores on a scale	Standard Error 7.35
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 31 (n=17,26)	10.3 scores on a scale	Standard Error 4.44
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 136 (n=0,2)	12.5 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 85 (n=2, 6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 139 (n=0,2)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Final Visit (n=157,160)	26.8 scores on a scale	Standard Error 2.02
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 37 (n=29,64)	9.5 scores on a scale	Standard Error 2.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: BL (n=275,287)	16.9 scores on a scale	Standard Error 1.12
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 4 (n=234,250)	16.0 scores on a scale	Standard Error 1.09
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 13 (n=152,182)	12.9 scores on a scale	Standard Error 1.34
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 43 (n=12,43)	6.2 scores on a scale	Standard Error 2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 16 (n=120,165)	14.4 scores on a scale	Standard Error 1.58
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 46 (n=14,42)	4.8 scores on a scale	Standard Error 1.82
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 19 (n=114,165)	10.6 scores on a scale	Standard Error 1.24
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 52 (n=8,30)	10.0 scores on a scale	Standard Error 3.26
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 25 (n=64,124)	9.7 scores on a scale	Standard Error 1.34
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 28 (n=47,111)	9.6 scores on a scale	Standard Error 1.42
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 40 (n=24,55)	9.5 scores on a scale	Standard Error 2.21
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 31 (n=45,95)	10.1 scores on a scale	Standard Error 1.93
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 58 (n=6,21)	14.3 scores on a scale	Standard Error 4.35
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 34 (n=45,95)	9.3 scores on a scale	Standard Error 1.77
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 34 (n=13,24)	16.7 scores on a scale	Standard Error 5.68
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 43 (n=12,43)	7.0 scores on a scale	Standard Error 1.88
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 127 (n=1,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 49 (n=10,36)	6.5 scores on a scale	Standard Error 1.43
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: BL (n=276,287)	16.6 scores on a scale	Standard Error 1.21
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 55 (n=6,24)	6.5 scores on a scale	Standard Error 2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 49 (n=10,36)	8.1 scores on a scale	Standard Error 1.83
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 58 (n=6,21)	5.3 scores on a scale	Standard Error 1.65
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 37 (n=12,16)	12.5 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 61 (n=4,17)	2.6 scores on a scale	Standard Error 1.52
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 7 (n=181,220)	12.8 scores on a scale	Standard Error 1.22
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 10 (n=176,203)	10.6 scores on a scale	Standard Error 1.19
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 67 (n=4,16)	6.3 scores on a scale	Standard Error 2.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 73 (n=3,12)	7.9 scores on a scale	Standard Error 2.6
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 130 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 76 (n=3,8)	1.4 scores on a scale	Standard Error 1.39
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 13 (n=152,183)	9.0 scores on a scale	Standard Error 1.09
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 79 (n=3,9)	3.7 scores on a scale	Standard Error 2.62
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 64 (n=3,20)	8.3 scores on a scale	Standard Error 2.42
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 16 (n=120,165)	9.1 scores on a scale	Standard Error 1.09
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 19 (n=114,143)	8.8 scores on a scale	Standard Error 1.26
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 106 (n=1,4)	2.8 scores on a scale	Standard Error 2.78
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 22 (n=79,143)	7.8 scores on a scale	Standard Error 1.19
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 109 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 112 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 40 (n=11,13)	12.8 scores on a scale	Standard Error 6.01
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 115 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 25 (n=64,124)	6.8 scores on a scale	Standard Error 1.27
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 124 (n=1,5)	6.7 scores on a scale	Standard Error 4.44
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 28 (n=47,111)	5.3 scores on a scale	Standard Error 1.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 130 (n=0,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 16 (n=119,165)	28.1 scores on a scale	Standard Error 2.29
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 31 (n=45,95)	6.8 scores on a scale	Standard Error 1.4
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 70 (n=3,14)	6.5 scores on a scale	Standard Error 2.34
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 139 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 34 (n=37,87)	7.5 scores on a scale	Standard Error 1.51
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 43 (n=5,9)	3.7 scores on a scale	Standard Error 3.7
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 73 (n=3,12)	9.0 scores on a scale	Standard Error 3.32
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 19 (n=114,143)	15.5 scores on a scale	Standard Error 1.53
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 40 (n=24,55)	6.5 scores on a scale	Standard Error 1.82
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 133 (n=1,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 43 (n=12,43)	5.2 scores on a scale	Standard Error 1.63
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 31 (n=45,95)	12.5 scores on a scale	Standard Error 2.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 34 (n=37,87)	10.9 scores on a scale	Standard Error 1.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 46 (n=14,42)	6.0 scores on a scale	Standard Error 1.31
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 76 (n=3,8)	5.2 scores on a scale	Standard Error 3.5
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 52 (n=8,30)	9.3 scores on a scale	Standard Error 2.31
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 46 (n=14,42)	2.9 scores on a scale	Standard Error 1.08
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 55 (n=6,24)	5.2 scores on a scale	Standard Error 1.86
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 58 (n=6,21)	6.0 scores on a scale	Standard Error 2.31
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 46 (n=5,13)	5.1 scores on a scale	Standard Error 3.47
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 61 (n=4,17)	5.4 scores on a scale	Standard Error 2.01
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 49 (n=10,36)	2.2 scores on a scale	Standard Error 0.74
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 67 (n=4,16)	10.4 scores on a scale	Standard Error 3.36
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 79 (n=3,9)	5.6 scores on a scale	Standard Error 3.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 85 (n=2,6)	4.2 scores on a scale	Standard Error 2.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 52 (n=8,30)	4.4 scores on a scale	Standard Error 1.81
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 91 (n=2,4)	4.2 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 94 (n=2,6)	4.2 scores on a scale	Standard Error 2.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Final Visit (n=61,60)	19.4 scores on a scale	Standard Error 3.29
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 55 (n=6,24)	3.7 scores on a scale	Standard Error 1.28
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 82 (n=2,6)	2.8 scores on a scale	Standard Error 2.78
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 112 (n=1,5)	3.3 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 58 (n=6,21)	3.2 scores on a scale	Standard Error 1.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 121 (n=1,5)	5.0 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 49 (n=4,7)	9.5 scores on a scale	Standard Error 6.15
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 124 (n=1,5)	1.7 scores on a scale	Standard Error 1.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 61 (n=4,17)	0.7 scores on a scale	Standard Error 0.65
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 127 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 88 (n=2,6)	4.2 scores on a scale	Standard Error 1.86
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 130 (n=0,3)	8.3 scores on a scale	Standard Error 4.81
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 64 (n=3,20)	3.3 scores on a scale	Standard Error 1.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 106 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Final Visit (n=157,160)	22.8 scores on a scale	Standard Error 1.84
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: BL (n=276,287)	48.2 scores on a scale	Standard Error 1.54
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 7 (n=181,220)	39.3 scores on a scale	Standard Error 1.66
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 10 (n=176,203)	38.2 scores on a scale	Standard Error 1.7
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 67 (n=4,16)	2.8 scores on a scale	Standard Error 2.15
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 13 (n=152,183)	37.5 scores on a scale	Standard Error 1.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 97 (n=1,5)	6.7 scores on a scale	Standard Error 3.12
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 70 (n=3,14)	3.2 scores on a scale	Standard Error 2.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 25 (n=64,124)	29.2 scores on a scale	Standard Error 2.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 100 (n=1,4)	6.3 scores on a scale	Standard Error 3.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 31 (n=45,95)	28.4 scores on a scale	Standard Error 2.32
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 73 (n=3,12)	4.6 scores on a scale	Standard Error 2.54
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 103 (n=1,4)	6.3 scores on a scale	Standard Error 3.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 55 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 55 (n=6,24)	28.2 scores on a scale	Standard Error 3.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 58 (n=6,21)	21.7 scores on a scale	Standard Error 3.38
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 85 (n=2,6)	1.9 scores on a scale	Standard Error 1.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 61 (n=4,17)	25.5 scores on a scale	Standard Error 5.37
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 73 (n=3,12)	28.7 scores on a scale	Standard Error 6.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 106 (n=1,4)	4.2 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 85 (n=2,6)	24.1 scores on a scale	Standard Error 3.41
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 94 (n=2,6)	1.9 scores on a scale	Standard Error 1.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 91 (n=2,4)	22.2 scores on a scale	Standard Error 4.54
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 100 (n=1,4)	16.7 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 106 (n=1,4)	19.4 scores on a scale	Standard Error 5.32
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 58 (n=2,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 109 (n=1,4)	16.7 scores on a scale	Standard Error 7.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 97 (n=1,5)	2.2 scores on a scale	Standard Error 2.22
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 124 (n=1,5)	17.8 scores on a scale	Standard Error 5.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 127 (n=1,3)	22.2 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 109 (n=1,4)	4.2 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 136 (n=0,2)	16.7 scores on a scale	Standard Error 16.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 100 (n=1,4)	2.8 scores on a scale	Standard Error 2.78
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Final Visit (n=157,160)	40.9 scores on a scale	Standard Error 2.22
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 121 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 103 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 115 (n=1,4)	4.2 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 16 (n=120,165)	23.4 scores on a scale	Standard Error 2.19
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 106 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 22 (n=79,143)	16.3 scores on a scale	Standard Error 2.06
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 61 (n=1,2)	16.7 scores on a scale	Standard Error 16.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 25 (n=64,124)	12.1 scores on a scale	Standard Error 1.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 28 (n=47,111)	10.8 scores on a scale	Standard Error 1.55
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 112 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 31 (n=45,95)	11.2 scores on a scale	Standard Error 2.21
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 34 (n=37,87)	9.6 scores on a scale	Standard Error 1.88
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 118 (n=1,5)	6.7 scores on a scale	Standard Error 3.12
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 37 (n=29,64)	9.4 scores on a scale	Standard Error 2.28
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 64 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 40 (n=23,55)	7.3 scores on a scale	Standard Error 2.4
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 118 (n=1,5)	2.2 scores on a scale	Standard Error 2.22
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 49 (n=10,36)	6.5 scores on a scale	Standard Error 2.23
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 4 (n=234,250)	12.5 scores on a scale	Standard Error 1.01
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 121 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 55 (n=6,24)	8.3 scores on a scale	Standard Error 3.01
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 73 (n=3,12)	27.8 scores on a scale	Standard Error 9.02
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 61 (n=4,17)	11.8 scores on a scale	Standard Error 4.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 127 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 64 (n=3,20)	6.7 scores on a scale	Standard Error 3.06
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 67 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 67 (n=4,16)	8.3 scores on a scale	Standard Error 4.81
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 70 (n=3,14)	11.9 scores on a scale	Standard Error 5.64
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 73 (n=3,12)	13.9 scores on a scale	Standard Error 4.95
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 130 (n=0,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 79 (n=3,9)	11.1 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 133 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 82 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 127 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 79 (n=3,9)	25.9 scores on a scale	Standard Error 9.26
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dysphagia Scale: Week 139 (n=0,2)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 97 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 82 (n=2,6)	16.7 scores on a scale	Standard Error 7.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 100 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: BL (n=276,287)	27.0 scores on a scale	Standard Error 1.2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 103 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 7 (n=181,219)	20.1 scores on a scale	Standard Error 1.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 10 (n=176,203)	17.5 scores on a scale	Standard Error 1.14
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 109 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 70 (n=1,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 112 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 85 (n=2,6)	11.1 scores on a scale	Standard Error 7.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 115 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 19 (n=114,143)	16.3 scores on a scale	Standard Error 1.32
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 118 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 121 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 124 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 28 (n=47,111)	14.0 scores on a scale	Standard Error 1.64
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 34 (n=37,87)	12.5 scores on a scale	Standard Error 2.04
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 130 (n=0,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 133 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 40 (n=24,55)	11.8 scores on a scale	Standard Error 2.28
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 136 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 43 (n=12,43)	9.7 scores on a scale	Standard Error 1.98
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 88 (n=2,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 76 (n=3,8)	20.8 scores on a scale	Standard Error 8.77
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Final Visit (n=157,157)	23.6 scores on a scale	Standard Error 2.43
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 73 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: BL (n=275,286)	17.9 scores on a scale	Standard Error 1.64
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 49 (n=10,36)	9.5 scores on a scale	Standard Error 1.79
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 4 (n=234,249)	24.8 scores on a scale	Standard Error 1.79
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 91 (n=2,4)	16.7 scores on a scale	Standard Error 9.62
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 7 (n=179,217)	24.0 scores on a scale	Standard Error 1.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 52 (n=8,30)	8.6 scores on a scale	Standard Error 2.69
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 10 (n=176,200)	25.3 scores on a scale	Standard Error 2.01
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 139 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 13 (n=151,181)	25.2 scores on a scale	Standard Error 2.2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 58 (n=6,21)	6.3 scores on a scale	Standard Error 1.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 16 (n=119,165)	23.8 scores on a scale	Standard Error 2.23
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 94 (n=2,6)	16.7 scores on a scale	Standard Error 7.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 19 (n=113,143)	22.6 scores on a scale	Standard Error 2.26
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 67 (n=4,16)	8.3 scores on a scale	Standard Error 2.95
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 22 (n=79,143)	19.6 scores on a scale	Standard Error 2.15
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 76 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 97 (n=1,5)	13.3 scores on a scale	Standard Error 8.16
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 28 (n=47,111)	14.7 scores on a scale	Standard Error 2.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 142 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 31 (n=45,95)	13.0 scores on a scale	Standard Error 2.65
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Dry Mouth: Week 88 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 34 (n=37,87)	9.6 scores on a scale	Standard Error 2.1
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 37 (n=28,64)	7.8 scores on a scale	Standard Error 2.2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 43 (n=12,43)	7.0 scores on a scale	Standard Error 2.09
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 103 (n=1,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 46 (n=14,42)	7.9 scores on a scale	Standard Error 2.74
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 76 (n=3,8)	5.2 scores on a scale	Standard Error 2.19
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 82 (n=2,6)	6.9 scores on a scale	Standard Error 3.98
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 52 (n=8,30)	7.8 scores on a scale	Standard Error 3.46
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 79 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 55 (n=6,24)	4.2 scores on a scale	Standard Error 2.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 85 (n=2,6)	5.6 scores on a scale	Standard Error 4.12
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 58 (n=6,21)	4.8 scores on a scale	Standard Error 2.61
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 106 (n=1,4)	16.7 scores on a scale	Standard Error 9.62
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 61 (n=4,17)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 88 (n=2,6)	5.6 scores on a scale	Standard Error 2.78
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 64 (n=3,20)	1.7 scores on a scale	Standard Error 1.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 82 (n=1,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 67 (n=4,16)	4.2 scores on a scale	Standard Error 2.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 70 (n=3,14)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 73 (n=3,12)	2.8 scores on a scale	Standard Error 2.78
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 94 (n=2,6)	5.6 scores on a scale	Standard Error 3.51
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 76 (n=3,8)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 109 (n=1,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 82 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 85 (n=1,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 88 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 100 (n=1,4)	6.3 scores on a scale	Standard Error 2.08
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 94 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 100 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 97 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 118 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 103 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 109 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 91 (n=1,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 112 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 109 (n=1,4)	4.2 scores on a scale	Standard Error 2.41
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 118 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 118 (n=1,5)	8.3 scores on a scale	Standard Error 3.73
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 124 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 121 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 127 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 121 (n=1,5)	10.0 scores on a scale	Standard Error 4.86
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 130 (n=0,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 136 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 25 (n=64,124)	15.9 scores on a scale	Standard Error 1.96
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 124 (n=1,5)	8.3 scores on a scale	Standard Error 3.73
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 142 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 124 (n=1,5)	6.67 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Final Visit (n=157,158)	20.3 scores on a scale	Standard Error 2.28
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 94 (n=1,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: BL (n=272,286)	31.9 scores on a scale	Standard Error 1.93
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 142 (n=0,2)	8.3 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 4 (n=233,249)	31.7 scores on a scale	Standard Error 2.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 7 (n=180,219)	27.9 scores on a scale	Standard Error 1.94
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 10 (n=175,203)	28.4 scores on a scale	Standard Error 2.05
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 13 (n=152,182)	28.2 scores on a scale	Standard Error 2.36
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Pain Scale: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 19 (n=114,140)	25.0 scores on a scale	Standard Error 2.53
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 22 (n=79,143)	22.4 scores on a scale	Standard Error 2.29
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 130 (n=0,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 25 (n=64,124)	22.6 scores on a scale	Standard Error 2.6
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 97 (n=1,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 28 (n=47,111)	20.1 scores on a scale	Standard Error 2.53
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 31 (n=45,95)	19.3 scores on a scale	Standard Error 2.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 133 (n=1,3)	11.1 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 34 (n=37,87)	18.0 scores on a scale	Standard Error 2.66
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 37 (n=29,64)	18.2 scores on a scale	Standard Error 3.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 7 (n=180,220)	15.4 scores on a scale	Standard Error 1.2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 40 (n=24,55)	19.4 scores on a scale	Standard Error 3.53
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 133 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 43 (n=12,43)	15.5 scores on a scale	Standard Error 3.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 10 (n=176,203)	13.5 scores on a scale	Standard Error 1.18
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 49 (n=10,36)	13.9 scores on a scale	Standard Error 4.07
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 136 (n=0,2)	16.7 scores on a scale	Standard Error 16.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 40 (n=24,55)	7.9 scores on a scale	Standard Error 2.73
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 58 (n=6,21)	15.9 scores on a scale	Standard Error 5.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 22 (n=79,143)	10.6 scores on a scale	Standard Error 1.37
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 61 (n=4,17)	13.7 scores on a scale	Standard Error 5.76
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 64 (n=3,20)	18.3 scores on a scale	Standard Error 4.51
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 139 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 67 (n=4,16)	14.6 scores on a scale	Standard Error 4.27
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 37 (n=29,64)	10.9 scores on a scale	Standard Error 2.38
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 70 (n=4,14)	16.7 scores on a scale	Standard Error 5.79
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 40 (n=24,55)	9.3 scores on a scale	Standard Error 2.13
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 76 (n=3,8)	37.5 scores on a scale	Standard Error 11.68
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 103 (n=1,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 100 (n=1,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 43 (n=12,42)	9.0 scores on a scale	Standard Error 2.07
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 112 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 142 (n=0,2)	16.7 scores on a scale	Standard Error 16.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 115 (n=1,4)	16.7 scores on a scale	Standard Error 9.62
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 127 (n=1,3)	11.1 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 7 (n=65,82)	19.1 scores on a scale	Standard Error 3.01
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 25 (n=24,49)	18.4 scores on a scale	Standard Error 3.64
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 46 (n=14,42)	6.6 scores on a scale	Standard Error 1.97
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 52 (n=3,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 52 (n=8,30)	8.1 scores on a scale	Standard Error 2.55
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 106 (n=1,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 64 (n=3,20)	3.9 scores on a scale	Standard Error 1.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 88 (n=1,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 70 (n=3,13)	4.3 scores on a scale	Standard Error 2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 100 (n=1,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 106 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 82 (n=2,6)	5.6 scores on a scale	Standard Error 2.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Final Visit (n=157,159)	30.4 scores on a scale	Standard Error 2.42
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 133 (n=1,3)	5.6 scores on a scale	Standard Error 2.78
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 109 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 136 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 139 (n=0,2)	4.2 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 142 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: BL (n=64,76)	25.0 scores on a scale	Standard Error 3.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	ER Scale: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 49 (n=9,36)	4.6 scores on a scale	Standard Error 1.95
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 4 (n=234,250)	43.8 scores on a scale	Standard Error 1.6
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 97 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 100 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 16 (n=120,165)	37.1 scores on a scale	Standard Error 2.1
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 19 (n=114,143)	34.9 scores on a scale	Standard Error 2.04
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 4 (n=68,71)	16.4 scores on a scale	Standard Error 2.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 22 (n=79,143)	32.8 scores on a scale	Standard Error 2.05
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 28 (n=47,111)	26.9 scores on a scale	Standard Error 1.88
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 103 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 112 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 34 (n=37,87)	27.8 scores on a scale	Standard Error 2.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 37 (n=29,64)	28.2 scores on a scale	Standard Error 2.87
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 46 (n=14,42)	15.9 scores on a scale	Standard Error 3.81
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 40 (n=24,55)	26.3 scores on a scale	Standard Error 2.77
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 10 (n=75,78)	20.1 scores on a scale	Standard Error 2.81
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 43 (n=12,43)	25.1 scores on a scale	Standard Error 2.91
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 46 (n=14,42)	23.3 scores on a scale	Standard Error 3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 118 (n=1,5)	4.4 scores on a scale	Standard Error 4.44
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 49 (n=14,42)	25.9 scores on a scale	Standard Error 3.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 52 (n=8,30)	27.4 scores on a scale	Standard Error 4.15
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 115 (n=1,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 121 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Hair Loss: Week 13 (n=66,80)	20.4 scores on a scale	Standard Error 3.05
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 64 (n=3,20)	23.9 scores on a scale	Standard Error 4.21
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 127 (n=1,3)	7.4 scores on a scale	Standard Error 7.41
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 67 (n=4,16)	18.8 scores on a scale	Standard Error 3.47
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 52 (n=8,30)	16.7 scores on a scale	Standard Error 3.83
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 70 (n=3,14)	27.0 scores on a scale	Standard Error 5.91
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 133 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Reflux Symptoms Scale: Week 136 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 76 (n=3,8)	27.8 scores on a scale	Standard Error 8.13
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 79 (n=3,9)	33.3 scores on a scale	Standard Error 8.28
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Body Image: Week 55 (n=6,24)	16.7 scores on a scale	Standard Error 4.91
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Anxiety Scale: Week 82 (n=2,6)	25.9 scores on a scale	Standard Error 8.92
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores	Taste: Week 139 (n=0,2)	0.0 scores on a scale	Standard Error 0

Secondary

European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score equals (=) better level of functioning or greater degree of symptoms.

Time frame: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS; n (number) = number of participants assessed for a specific parameter at a given visit.

Arm	Measure	Group	Value (MEAN)	Dispersion
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 127 (n=1,3)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 7 (n=179,220)	19.0 scores on a scale	Standard Error 2.01
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 133 (n=1,3)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 133 (n=1,3)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 43 (n=12,43)	2.8 scores on a scale	Standard Error 1.87
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 43 (n=12,43)	8.3 scores on a scale	Standard Error 4.35
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Final Visit (n=158,161)	79.5 scores on a scale	Standard Error 1.82
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 55 (n=6,24)	94.4 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: BL (n=276,286)	72.4 scores on a scale	Standard Error 1.63
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 4 (n=235,250)	72.1 scores on a scale	Standard Error 1.66
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 58 (n=6,21)	11.1 scores on a scale	Standard Error 7.03
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 7 (n=179,220)	73.1 scores on a scale	Standard Error 1.88
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 10 (n=176,202)	74.5 scores on a scale	Standard Error 1.84
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 46 (n=14,42)	1.2 scores on a scale	Standard Error 1.19
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 13 (n=152,183)	72.7 scores on a scale	Standard Error 2.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Final Visit (n=158,160)	53.2 scores on a scale	Standard Error 2.09
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 16 (n=180,165)	72.7 scores on a scale	Standard Error 2.52
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 19 (n=114,143)	74.4 scores on a scale	Standard Error 2.41
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: BL (n=276,287)	78.9 scores on a scale	Standard Error 1.16
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 22 (n=79,143)	79.3 scores on a scale	Standard Error 2.77
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 25 (n=64,124)	83.3 scores on a scale	Standard Error 2.43
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 28 (n=47,111)	83.0 scores on a scale	Standard Error 3.38
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 7 (n=181,220)	79.3 scores on a scale	Standard Error 1.37
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 34 (n=37,87)	84.7 scores on a scale	Standard Error 3.06
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 10 (n=174,201)	78.2 scores on a scale	Standard Error 1.47
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 37 (n=29,64)	85.1 scores on a scale	Standard Error 4.48
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 49 (n=10,36)	3.3 scores on a scale	Standard Error 2.22
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 40 (n=24,55)	85.4 scores on a scale	Standard Error 4.05
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 13 (n=151,183)	80.2 scores on a scale	Standard Error 1.53
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 43 (n=12,43)	87.5 scores on a scale	Standard Error 4.64
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 61 (n=4,17)	8.3 scores on a scale	Standard Error 5.32
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 46 (n=14,42)	86.9 scores on a scale	Standard Error 4.34
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 16 (n=121,165)	79.8 scores on a scale	Standard Error 1.58
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 49 (n=10,36)	85.0 scores on a scale	Standard Error 5.24
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 52 (n=8,29)	87.5 scores on a scale	Standard Error 6.1
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 19 (n=114,143)	78.8 scores on a scale	Standard Error 1.81
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 55 (n=6,24)	86.1 scores on a scale	Standard Error 6.69
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 52 (n=8,30)	2.1 scores on a scale	Standard Error 2.08
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 61 (n=4,17)	91.7 scores on a scale	Standard Error 4.81
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 22 (n=79,143)	80.7 scores on a scale	Standard Error 2.2
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 64 (n=3,20)	94.4 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 67 (n=4,17)	95.8 scores on a scale	Standard Error 4.17
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 25 (n=64,124)	85.8 scores on a scale	Standard Error 2.07
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 70 (n=3,14)	94.4 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 64 (n=3,20)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 73 (n=3,12)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 28 (n=47,110)	86.2 scores on a scale	Standard Error 2.5
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 76 (n=3,8)	94.4 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 79 (n=3,9)	94.4 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Wek 82 (n=2,6)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 31 (n=45,95)	85.6 scores on a scale	Standard Error 2.45
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 85 (n=2,6)	91.7 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 73 (n=3,12)	7.4 scores on a scale	Standard Error 3.7
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 88 (n=2,6)	91.7 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 34 (n=37,87)	86.3 scores on a scale	Standard Error 2.5
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 91 (n=2,4)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 76 (n=3,8)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 94 (n=2,6)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 37 (n=29,64)	85.7 scores on a scale	Standard Error 3.43
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 97 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 37 (n=29,64)	5.7 scores on a scale	Standard Error 2.38
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 40 (n=24,55)	84.4 scores on a scale	Standard Error 3.51
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 103 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 70 (n=3,14)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 106 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 43 (n=12,43)	85.6 scores on a scale	Standard Error 3.75
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 109 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 91 (n=2,4)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 115 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 46 (n=14,42)	87.6 scores on a scale	Standard Error 3.03
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 118 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 76 (n=3,8)	22.2 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 70 (n=3,14)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 124 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 127 (n=1,3)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 52 (n=8,30)	88.3 scores on a scale	Standard Error 3.93
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 133 (n=1,3)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 55 (n=6,24)	85.6 scores on a scale	Standard Error 5.28
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 58 (n=6,21)	86.7 scores on a scale	Standard Error 5.71
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Final Visit (n=158,161)	68.1 scores on a scale	Standard Error 2.41
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 61 (n=4,17)	91.7 scores on a scale	Standard Error 5
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: BL (n=276,287)	36.3 scores on a scale	Standard Error 1.37
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 4 (n=235,250)	37.1 scores on a scale	Standard Error 1.47
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 64 (n=3,20)	95.6 scores on a scale	Standard Error 4.44
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 7 (n=181,220)	34.4 scores on a scale	Standard Error 1.54
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 70 (n=3,14)	77.8 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 10 (n=176,201)	35.3 scores on a scale	Standard Error 1.7
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 67 (n=4,17)	93.3 scores on a scale	Standard Error 4.71
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 13 (n=152,183)	32.9 scores on a scale	Standard Error 1.7
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 16 (n=121,165)	33.0 scores on a scale	Standard Error 2.09
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 19 (n=114,143)	33.1 scores on a scale	Standard Error 2.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 73 (n=3,12)	97.8 scores on a scale	Standard Error 2.22
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 25 (n=64,124)	22.2 scores on a scale	Standard Error 2.55
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 28 (n=47,110)	24.1 scores on a scale	Standard Error 3.16
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 31 (n=45,95)	22.0 scores on a scale	Standard Error 2.92
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 76 (n=3,8)	95.6 scores on a scale	Standard Error 4.44
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 34 (n=37,87)	22.8 scores on a scale	Standard Error 3.63
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 37 (n=29,64)	21.8 scores on a scale	Standard Error 4.63
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 40 (n=24,55)	23.6 scores on a scale	Standard Error 4.45
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 82 (n=2,6)	93.3 scores on a scale	Standard Error 6.67
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 43 (n=12,43)	19.4 scores on a scale	Standard Error 3.9
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 46 (n=14,42)	20.6 scores on a scale	Standard Error 4.18
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 49 (n=10,36)	19.4 scores on a scale	Standard Error 3.23
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 52 (n=8,30)	16.7 scores on a scale	Standard Error 2.97
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 85 (n=2,6)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 55 (n=6,24)	18.5 scores on a scale	Standard Error 5.49
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 4 (n=235,250)	76.0 scores on a scale	Standard Error 1.27
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 58 (n=6,21)	16.7 scores on a scale	Standard Error 4.76
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 88 (n=2,6)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 64 (n=3,20)	7.4 scores on a scale	Standard Error 3.7
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: BL (n=274,286)	27.3 scores on a scale	Standard Error 1.91
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 67 (n=4,17)	13.9 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 91 (n=2,4)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 70 (n=3,14)	11.1 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 94 (n=2,6)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 76 (n=3,8)	7.4 scores on a scale	Standard Error 3.7
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 4 (n=234,249)	23.6 scores on a scale	Standard Error 1.93
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 79 (n=3,9)	7.4 scores on a scale	Standard Error 3.7
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 97 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 85 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 100 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 7 (n=178,220)	23.6 scores on a scale	Standard Error 2.08
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 103 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 7 (n=181,217)	12.7 scores on a scale	Standard Error 1.66
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 97 (n=1,5)	11.1 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 106 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 10 (n=175,202)	21.5 scores on a scale	Standard Error 2.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 106 (n=1,4)	11.1 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 109 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 112 (n=1,5)	93.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 19 (n=113,143)	20.6 scores on a scale	Standard Error 2.53
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 115 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 40 (n=24,55)	9.7 scores on a scale	Standard Error 3.74
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 118 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 121 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 22 (n=78,142)	19.7 scores on a scale	Standard Error 3.01
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 55 (n=6,24)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 124 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 58 (n=6,21)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 52 (n=8,30)	12.5 scores on a scale	Standard Error 6.1
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 61 (n=4,17)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 127 (n=1,3)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 64 (n=3,20)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 67 (n=4,17)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 25 (n=63,124)	16.4 scores on a scale	Standard Error 3.01
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 70 (n=3,14)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 73 (n=3,12)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 76 (n=3,8)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 133 (n=1,3)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 28 (n=45,111)	17.0 scores on a scale	Standard Error 3.76
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 31 (n=45,94)	15.6 scores on a scale	Standard Error 3.76
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 85 (n=180,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 34 (n=36,87)	10.2 scores on a scale	Standard Error 2.92
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Final Visit (n=158,161)	72.1 scores on a scale	Standard Error 1.97
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: BL (n=276,287)	73.2 scores on a scale	Standard Error 1.7
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 37 (n=29,64)	13.8 scores on a scale	Standard Error 4.83
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 4 (n=234,250)	67.4 scores on a scale	Standard Error 1.85
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 7 (n=181,220)	70.9 scores on a scale	Standard Error 1.99
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 40 (n=24,55)	22.2 scores on a scale	Standard Error 5.18
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 10 (n=176,202)	70.2 scores on a scale	Standard Error 2.06
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 13 (n=152,182)	73.4 scores on a scale	Standard Error 2.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 43 (n=12,43)	16.7 scores on a scale	Standard Error 7.68
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 16 (n=121,165)	72.0 scores on a scale	Standard Error 2.41
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Final Visit (n=158,161)	14.9 scores on a scale	Standard Error 1.79
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 61 (n=4,17)	79.2 scores on a scale	Standard Error 7.98
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: BL (n=276,287)	24.9 scores on a scale	Standard Error 1.46
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 19 (n=114,143)	71.1 scores on a scale	Standard Error 2.21
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 4 (n=235,250)	17.8 scores on a scale	Standard Error 1.43
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 46 (n=14,42)	16.7 scores on a scale	Standard Error 5.79
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 7 (n=181,220)	14.5 scores on a scale	Standard Error 1.43
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 22 (n=79,142)	74.7 scores on a scale	Standard Error 2.81
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 10 (n=176,202)	13.4 scores on a scale	Standard Error 1.34
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 13 (n=152,183)	12.0 scores on a scale	Standard Error 1.42
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 25 (n=64,124)	81.3 scores on a scale	Standard Error 2.93
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 16 (n=121,165)	13.6 scores on a scale	Standard Error 1.8
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 49 (n=10,35)	16.7 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 19 (n=114,143)	14.2 scores on a scale	Standard Error 1.98
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 28 (n=47,110)	80.5 scores on a scale	Standard Error 3.52
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 22 (n=79,143)	15.0 scores on a scale	Standard Error 2.59
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 25 (n=64,124)	10.7 scores on a scale	Standard Error 2.44
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 28 (n=47,111)	8.2 scores on a scale	Standard Error 1.82
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 31 (n=45,95)	82.2 scores on a scale	Standard Error 2.87
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 31 (n=45,95)	12.2 scores on a scale	Standard Error 2.97
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 34 (n=37,87)	83.3 scores on a scale	Standard Error 3.1
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 34 (n=37,87)	12.2 scores on a scale	Standard Error 3
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 52 (n=8,29)	8.3 scores on a scale	Standard Error 5.46
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 37 (n=29,64)	11.5 scores on a scale	Standard Error 2.99
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 37 (n=29,64)	81.6 scores on a scale	Standard Error 4.16
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 40 (n=24,55)	18.8 scores on a scale	Standard Error 4.74
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 43 (n=12,43)	16.7 scores on a scale	Standard Error 5.03
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 40 (n=24,55)	79.9 scores on a scale	Standard Error 4.91
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 46 (n=14,42)	13.1 scores on a scale	Standard Error 3.57
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 55 (n=6,24)	16.7 scores on a scale	Standard Error 11.39
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 49 (n=10,36)	13.3 scores on a scale	Standard Error 4.84
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 43 (n=12,43)	80.6 scores on a scale	Standard Error 4.95
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 52 (n=8,30)	6.3 scores on a scale	Standard Error 3.05
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 31 (n=45,95)	81.5 scores on a scale	Standard Error 3.9
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 55 (n=6,24)	2.8 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 46 (n=14,42)	82.1 scores on a scale	Standard Error 4.44
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 58 (n=6,21)	8.3 scores on a scale	Standard Error 5.69
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 58 (n=6,21)	11.1 scores on a scale	Standard Error 7.03
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 61 (n=4,17)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 49 (n=10,36)	81.7 scores on a scale	Standard Error 6.78
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 64 (n=3,20)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 67 (n=4,17)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 52 (n=8,30)	85.4 scores on a scale	Standard Error 5.84
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 61 (n=4,17)	16.7 scores on a scale	Standard Error 9.62
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 73 (n=3,12)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 55 (n=6,24)	80.6 scores on a scale	Standard Error 5.12
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 76 (n=3,8)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Final Visit (n=158,160)	40.4 scores on a scale	Standard Error 2.17
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 79 (n=3,9)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 58 (n=6,21)	77.8 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 64 (n=3,20)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 61 (n=4,17)	83.3 scores on a scale	Standard Error 9.62
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 64 (n=3,20)	83.3 scores on a scale	Standard Error 9.62
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 67 (n=4,17)	16.7 scores on a scale	Standard Error 9.62
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 67 (n=4,17)	83.3 scores on a scale	Standard Error 6.8
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 49 (n=10,36)	88.7 scores on a scale	Standard Error 3.45
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 70 (n=3,14)	88.9 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 70 (n=3,14)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 73 (n=3,12)	88.9 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 76 (n=3,8)	83.3 scores on a scale	Standard Error 9.62
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 79 (n=3,9)	83.3 scores on a scale	Standard Error 9.62
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 73 (n=3,12)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 82 (n=2,6)	91.7 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 85 (n=2,6)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 76 (n=3,8)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Final Visit (n=158,161)	27.4 scores on a scale	Standard Error 2.34
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 88 (n=2,6)	91.7 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: BL (n=274,281)	12.4 scores on a scale	Standard Error 1.25
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: BL (n=276,287)	15.0 scores on a scale	Standard Error 1.39
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 4 (n=232,249)	12.1 scores on a scale	Standard Error 1.35
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 91 (n=2,4)	91.7 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 94 (n=2,6)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 10 (n=176,198)	14.6 scores on a scale	Standard Error 1.71
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 79 (n=3,9)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 13 (n=151,182)	11.3 scores on a scale	Standard Error 1.8
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 97 (n=1,5)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 16 (n=121,165)	15.4 scores on a scale	Standard Error 2.28
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 4 (n=234,248)	22.1 scores on a scale	Standard Error 1.82
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 19 (n=113,143)	15.3 scores on a scale	Standard Error 2.48
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 100 (n=1,4)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 22 (n=79,143)	13.9 scores on a scale	Standard Error 2.79
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 82 (n=2,6)	16.7 scores on a scale	Standard Error 16.67
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 25 (n=63,124)	12.7 scores on a scale	Standard Error 2.76
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 28 (n=47,110)	9.2 scores on a scale	Standard Error 2.42
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 103 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 31 (n=45,95)	10.4 scores on a scale	Standard Error 2.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 58 (n=6,21)	88.9 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 34 (n=36,87)	10.2 scores on a scale	Standard Error 2.92
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 106 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 37 (n=29,64)	10.3 scores on a scale	Standard Error 3.35
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 85 (n=2,6)	16.7 scores on a scale	Standard Error 16.67
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 109 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 43 (n=12,43)	19.4 scores on a scale	Standard Error 7.63
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 7 (n=181,219)	21.9 scores on a scale	Standard Error 2.1
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 46 (n=14,42)	11.9 scores on a scale	Standard Error 4.43
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 112 (n=1,5)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 49 (n=10,36)	6.7 scores on a scale	Standard Error 4.44
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 4 (n=235,250)	16.6 scores on a scale	Standard Error 1.45
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 115 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 55 (n=6,24)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 91 (n=2,4)	16.7 scores on a scale	Standard Error 16.67
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 58 (n=6,21)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 118 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 61 (n=4,17)	16.7 scores on a scale	Standard Error 9.62
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 10 (n=175,200)	19.8 scores on a scale	Standard Error 2.04
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 64 (n=3,20)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 121 (n=1,5)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 67 (n=4,17)	8.3 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 94 (n=2,6)	16.7 scores on a scale	Standard Error 16.67
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 70 (n=3,14)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 73 (n=3,12)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 124 (n=1,5)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 76 (n=3,8)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 13 (n=152,183)	14.7 scores on a scale	Standard Error 1.86
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 127 (n=1,3)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 133 (n=1,3)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 16 (n=120,164)	15.3 scores on a scale	Standard Error 1.93
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 10 (n=176,201)	16.4 scores on a scale	Standard Error 1.67
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Final Visit (n=158,161)	63.5 scores on a scale	Standard Error 2.46
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 19 (n=113,143)	17.1 scores on a scale	Standard Error 2.3
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 7 (n=181,220)	16.9 scores on a scale	Standard Error 1.66
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: BL (n=276,287)	75.4 scores on a scale	Standard Error 1.26
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 4 (n=235,250)	80.5 scores on a scale	Standard Error 1.25
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 100 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 7 (n=180,220)	81.3 scores on a scale	Standard Error 1.39
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 10 (n=176,202)	82.9 scores on a scale	Standard Error 1.39
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 13 (n=121,183)	12.8 scores on a scale	Standard Error 1.41
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 13 (n=152,183)	82.6 scores on a scale	Standard Error 1.48
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 88 (n=2,6)	16.7 scores on a scale	Standard Error 16.67
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 16 (n=121,165)	83.1 scores on a scale	Standard Error 1.81
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Final Visit (n=157,160)	21.9 scores on a scale	Standard Error 2.29
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 28 (n=47,110)	9.9 scores on a scale	Standard Error 3.03
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: BL (n=275,286)	35.2 scores on a scale	Standard Error 2.02
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 19 (n=114,143)	82.2 scores on a scale	Standard Error 1.95
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 4 (n=235,250)	31.5 scores on a scale	Standard Error 2.01
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 70 (n=3,14)	97.8 scores on a scale	Standard Error 2.22
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 7 (n=180,216)	27.2 scores on a scale	Standard Error 2.19
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 22 (n=79,143)	85.9 scores on a scale	Standard Error 2.06
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 10 (n=176,201)	26.7 scores on a scale	Standard Error 2.1
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 16 (n=121,165)	14.2 scores on a scale	Standard Error 1.99
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 25 (n=64,124)	88.2 scores on a scale	Standard Error 1.97
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 16 (n=121,165)	24.5 scores on a scale	Standard Error 2.27
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Final Visit (n=158,160)	26.6 scores on a scale	Standard Error 2.39
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 19 (n=114,141)	26.9 scores on a scale	Standard Error 2.81
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 28 (n=47,111)	86.0 scores on a scale	Standard Error 2.37
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 22 (n=79,143)	19.0 scores on a scale	Standard Error 2.92
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 46 (n=13,42)	75.0 scores on a scale	Standard Error 4
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 25 (n=64,124)	12.0 scores on a scale	Standard Error 2.39
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 31 (n=45,95)	85.7 scores on a scale	Standard Error 2.24
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 28 (n=47,109)	14.2 scores on a scale	Standard Error 2.82
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 37 (n=29,63)	8.0 scores on a scale	Standard Error 3.16
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 34 (n=37,87)	88.5 scores on a scale	Standard Error 2.29
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 34 (n=37,87)	11.7 scores on a scale	Standard Error 2.65
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 49 (n=9,36)	68.5 scores on a scale	Standard Error 5.69
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 37 (n=29,64)	12.6 scores on a scale	Standard Error 3.48
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 37 (n=29,64)	83.9 scores on a scale	Standard Error 3.43
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 43 (n=12,43)	13.9 scores on a scale	Standard Error 8.66
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 40 (n=24,55)	83.6 scores on a scale	Standard Error 3.99
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 52 (n=7,29)	72.6 scores on a scale	Standard Error 3.95
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 49 (n=9,36)	3.7 scores on a scale	Standard Error 3.7
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 52 (n=8,30)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 43 (n=12,43)	81.9 scores on a scale	Standard Error 5.21
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: BL (n=274,287)	55.3 scores on a scale	Standard Error 1.43
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 58 (n=6,21)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 46 (n=14,42)	82.1 scores on a scale	Standard Error 4.44
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 61 (n=4,17)	8.3 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 46 (n=13,42)	7.7 scores on a scale	Standard Error 4.05
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 64 (n=3,20)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 49 (n=10,36)	88.3 scores on a scale	Standard Error 4.16
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 67 (n=4,17)	8.3 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 4 (n=235,249)	61.0 scores on a scale	Standard Error 1.37
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 70 (n=3,14)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 52 (n=8,29)	86.5 scores on a scale	Standard Error 5.88
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 112 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 76 (n=3,8)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 55 (n=6,24)	76.4 scores on a scale	Standard Error 9.23
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 7 (n=180,220)	60.9 scores on a scale	Standard Error 1.54
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 58 (n=6,21)	85.6 scores on a scale	Standard Error 6.27
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 52 (n=8,30)	12.5 scores on a scale	Standard Error 6.1
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 61 (n=4,17)	95.8 scores on a scale	Standard Error 2.41
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 10 (n=176,202)	62.3 scores on a scale	Standard Error 1.58
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 64 (n=3,20)	100 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 55 (n=6,24)	16.7 scores on a scale	Standard Error 7.45
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 67 (n=4,17)	95.8 scores on a scale	Standard Error 2.41
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 34 (n=36,87)	70.8 scores on a scale	Standard Error 3.55
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 109 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 70 (n=3,14)	97.2 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 13 (n=152,182)	63.8 scores on a scale	Standard Error 1.77
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 73 (n=3,12)	94.4 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 19 (n=114,143)	14.2 scores on a scale	Standard Error 2.01
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 76 (n=3,8)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 37 (n=29,64)	66.1 scores on a scale	Standard Error 3.72
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 79 (n=3,9)	97.2 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 58 (n=6,21)	11.1 scores on a scale	Standard Error 7.03
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 82 (n=2,6)	95.8 scores on a scale	Standard Error 4.17
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 61 (n=4,17)	8.3 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 85 (n=2,6)	95.8 scores on a scale	Standard Error 4.17
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week Final Visit (n=156,161)	35.3 scores on a scale	Standard Error 2.45
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 16 (n=121,165)	60.8 scores on a scale	Standard Error 1.85
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: BL (n=276,285)	22.9 scores on a scale	Standard Error 1.79
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 88 (n=2,6)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 4 (n=235,247)	20.6 scores on a scale	Standard Error 1.85
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 121 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 10 (n=175,203)	19.2 scores on a scale	Standard Error 1.9
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 91 (n=2,4)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 13 (n=152,183)	16.7 scores on a scale	Standard Error 1.92
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 16 (n=121,165)	14.6 scores on a scale	Standard Error 1.99
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 19 (n=114,143)	61.0 scores on a scale	Standard Error 1.94
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 19 (n=114,143)	13.5 scores on a scale	Standard Error 2.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 94 (n=2,6)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 22 (n=78,143)	12.0 scores on a scale	Standard Error 2.27
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 67 (n=4,17)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 25 (n=64,124)	7.3 scores on a scale	Standard Error 2.4
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 97 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 28 (n=47,111)	7.8 scores on a scale	Standard Error 2.31
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 22 (n=78,143)	65.1 scores on a scale	Standard Error 2.32
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 31 (n=45,95)	10.4 scores on a scale	Standard Error 2.96
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 100 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 34 (n=37,86)	5.4 scores on a scale	Standard Error 2.05
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 22 (n=79,143)	10.3 scores on a scale	Standard Error 2.23
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 37 (n=29,64)	11.5 scores on a scale	Standard Error 3.8
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 103 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 40 (n=24,55)	8.3 scores on a scale	Standard Error 3.62
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 25 (n=64,124)	68.0 scores on a scale	Standard Error 2.65
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 106 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 46 (n=14,42)	4.8 scores on a scale	Standard Error 3.24
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 73 (n=3,12)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 49 (n=10,36)	3.3 scores on a scale	Standard Error 3.33
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 52 (n=8,29)	4.2 scores on a scale	Standard Error 4.17
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 109 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 55 (n=6,24)	5.6 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 40 (n=23,55)	62.0 scores on a scale	Standard Error 4.97
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 112 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 61 (n=4,17)	8.3 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 76 (n=3,8)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 64 (n=3,20)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 115 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 67 (n=4,17)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 28 (n=47,111)	72.0 scores on a scale	Standard Error 2.69
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 70 (n=3,14)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 118 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 73 (n=3,12)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 76 (n=3,8)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 121 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 82 (n=2,6)	16.7 scores on a scale	Standard Error 16.67
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 124 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 85 (n=2,6)	16.7 scores on a scale	Standard Error 16.67
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 31 (n=45,95)	69.6 scores on a scale	Standard Error 2.83
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 127 (n=1,3)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 43 (n=12,43)	72.9 scores on a scale	Standard Error 5.14
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 100 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 133 (n=1,3)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 103 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 55 (n=5,24)	76.7 scores on a scale	Standard Error 4.08
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 58 (n=5,21)	76.7 scores on a scale	Standard Error 4.08
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 25 (n=64,124)	8.6 scores on a scale	Standard Error 2.38
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 64 (n=3,20)	77.8 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Final Visit (n=158,161)	75.1 scores on a scale	Standard Error 2.16
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 79 (n=3,9)	95.6 scores on a scale	Standard Error 4.44
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Final Visit (n=158,160)	19.0 scores on a scale	Standard Error 2.12
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: BL (n=276,287)	86.9 scores on a scale	Standard Error 1.06
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: BL (n=276,283)	10.9 scores on a scale	Standard Error 1.21
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 28 (n=47,110)	3.5 scores on a scale	Standard Error 1.34
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 4 (n=234,246)	9.1 scores on a scale	Standard Error 1.25
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 4 (n=235,250)	86.0 scores on a scale	Standard Error 1.14
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 7 (n=180,220)	8.7 scores on a scale	Standard Error 1.4
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 67 (n=4,17)	75.0 scores on a scale	Standard Error 4.81
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 10 (n=174,202)	10.5 scores on a scale	Standard Error 1.51
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 7 (n=180,220)	85.7 scores on a scale	Standard Error 1.36
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 13 (n=152,183)	6.6 scores on a scale	Standard Error 1.21
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 31 (n=45,95)	3.7 scores on a scale	Standard Error 1.58
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 16 (n=120,165)	8.1 scores on a scale	Standard Error 1.63
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 10 (n=176,202)	85.6 scores on a scale	Standard Error 1.35
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 19 (n=114,143)	7.3 scores on a scale	Standard Error 1.7
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 22 (n=78,143)	6.0 scores on a scale	Standard Error 1.8
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 13 (n=152,183)	88.2 scores on a scale	Standard Error 1.34
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 25 (n=64,124)	7.3 scores on a scale	Standard Error 1.74
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 73 (n=3,12)	80.6 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 28 (n=47,111)	5.7 scores on a scale	Standard Error 1.85
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 16 (n=121,165)	82.8 scores on a scale	Standard Error 1.7
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 31 (n=45,95)	5.9 scores on a scale	Standard Error 1.92
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 34 (n=37,87)	5.4 scores on a scale	Standard Error 2.05
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 19 (n=114,143)	84.2 scores on a scale	Standard Error 1.62
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 76 (n=3,8)	77.8 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 40 (n=24,55)	6.9 scores on a scale	Standard Error 2.82
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 22 (n=79,143)	85.9 scores on a scale	Standard Error 1.92
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 43 (n=12,42)	8.3 scores on a scale	Standard Error 4.35
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 46 (n=14,42)	4.8 scores on a scale	Standard Error 3.24
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 79 (n=3,9)	77.8 scores on a scale	Standard Error 5.56
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 49 (n=10,36)	10.0 scores on a scale	Standard Error 5.09
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 28 (n=47,111)	86.5 scores on a scale	Standard Error 2.25
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 52 (n=8,29)	8.3 scores on a scale	Standard Error 5.46
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 34 (n=37,87)	4.5 scores on a scale	Standard Error 1.9
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 55 (n=6,24)	11.1 scores on a scale	Standard Error 7.03
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 31 (n=45,95)	87.0 scores on a scale	Standard Error 2.18
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 58 (n=6,21)	11.1 scores on a scale	Standard Error 7.03
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 82 (n=2,5)	83.3 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 61 (n=4,17)	16.7 scores on a scale	Standard Error 9.62
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 34 (n=37,87)	88.3 scores on a scale	Standard Error 2.49
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 64 (n=3,20)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 67 (n=4,17)	16.7 scores on a scale	Standard Error 9.62
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 37 (n=29,64)	88.5 scores on a scale	Standard Error 2.63
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 85 (n=2,6)	83.3 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 73 (n=3,12)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 40 (n=24,55)	83.3 scores on a scale	Standard Error 3.48
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 79 (n=3,9)	11.1 scores on a scale	Standard Error 11.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 13 (n=151,183)	24.7 scores on a scale	Standard Error 2.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 88 (n=2,6)	83.3 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 46 (n=14,42)	89.3 scores on a scale	Standard Error 3.75
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 31 (n=45,95)	11.1 scores on a scale	Standard Error 3.18
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 91 (n=2,4)	16.7 scores on a scale	Standard Error 16.67
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 49 (n=10,36)	85.0 scores on a scale	Standard Error 5.8
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 94 (n=2,6)	16.7 scores on a scale	Standard Error 16.67
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 91 (n=2,4)	83.3 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 97 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 52 (n=8,29)	91.7 scores on a scale	Standard Error 5.46
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 40 (n=24,55)	13.9 scores on a scale	Standard Error 3.97
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 106 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 94 (n=2,6)	83.3 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 58 (n=6,21)	91.7 scores on a scale	Standard Error 5.69
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 112 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 43 (n=12,43)	5.6 scores on a scale	Standard Error 3.75
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 61 (n=4,17)	91.7 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 97 (n=1,5)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 100 (n=1,4)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 127 (n=1,3)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 67 (n=4,17)	91.7 scores on a scale	Standard Error 8.33
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 46 (n=14,42)	4.8 scores on a scale	Standard Error 3.24
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 70 (n=3,14)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 103 (n=1,3)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Final Visit (n=157,160)	10.0 scores on a scale	Standard Error 1.55
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 73 (n=3,12)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 13 (n=151,181)	22.5 scores on a scale	Standard Error 2.23
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 22 (n=79,143)	30.0 scores on a scale	Standard Error 2.63
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 16 (n=120,165)	23.1 scores on a scale	Standard Error 2.58
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 106 (n=1,4)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 79 (n=3,9)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 124 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 55 (n=6,24)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 82 (n=2,6)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 109 (n=1,4)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 85 (n=2,6)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 73 (n=3,12)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Final Visit (n=157,160)	20.0 scores on a scale	Standard Error 2.13
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 88 (n=2,6)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: BL (n=276,285)	27.2 scores on a scale	Standard Error 1.86
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 112 (n=1,5)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 22 (n=79,143)	14.8 scores on a scale	Standard Error 2.38
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 115 (n=1,4)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 25 (n=64,124)	15.1 scores on a scale	Standard Error 3.05
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 31 (n=45,94)	10.4 scores on a scale	Standard Error 2.77
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 94 (n=2,6)	100.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 34 (n=37,87)	9.0 scores on a scale	Standard Error 2.78
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 37 (n=29,64)	2.9 scores on a scale	Standard Error 1.67
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 40 (n=24,55)	13.9 scores on a scale	Standard Error 4.45
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 97 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 100 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 49 (n=10,36)	10.0 scores on a scale	Standard Error 7.11
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 118 (n=1,5)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 103 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 25 (n=64,124)	85.9 scores on a scale	Standard Error 2.2
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 64 (n=3,20)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 106 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 70 (n=3,14)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 121 (n=1,5)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 109 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 112 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 40 (n=24,55)	4.2 scores on a scale	Standard Error 1.5
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 115 (n=1,4)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 115 (n=1,4)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 118 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 121 (n=1,5)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 124 (n=1,5)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 118 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 127 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 130 (n=0,3)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 133 (n=1,3)	0.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 121 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 136 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 139 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 142 (n=0,2)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 127 (n=1,3)	83.3 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 145 (n=0,1)	NA scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 124 (n=1,5)	100.0 scores on a scale	—
Fluoropyrimidine/Cisplatin (FP)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 43 (n=12,43)	88.9 scores on a scale	Standard Error 3.75
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Final Visit (n=158,160)	27.9 scores on a scale	Standard Error 2.51
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 52 (n=7,29)	71.3 scores on a scale	Standard Error 4.02
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 55 (n=5,24)	73.8 scores on a scale	Standard Error 4.68
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 97 (n=1,5)	78.3 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 112 (n=1,5)	75.0 scores on a scale	Standard Error 3.73
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 7 (n=181,220)	79.3 scores on a scale	Standard Error 1.25
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 118 (n=1,5)	96.0 scores on a scale	Standard Error 4
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 31 (n=45,95)	81.1 scores on a scale	Standard Error 2.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 76 (n=3,8)	81.3 scores on a scale	Standard Error 7.34
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 91 (n=2,4)	91.7 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 121 (n=1,5)	95.0 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 139 (n=0,2)	95.8 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 97 (n=1,5)	90.0 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 109 (n=1,4)	95.8 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 25 (n=64,124)	80.2 scores on a scale	Standard Error 1.78
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 55 (n=6,24)	85.4 scores on a scale	Standard Error 3.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 79 (n=3,9)	85.2 scores on a scale	Standard Error 7.58
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 109 (n=1,4)	95.8 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 124 (n=1,5)	96.7 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 127 (n=1,3)	83.3 scores on a scale	Standard Error 9.62
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 19 (n=114,143)	29.4 scores on a scale	Standard Error 1.87
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 28 (n=47,110)	23.2 scores on a scale	Standard Error 1.93
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 46 (n=14,42)	13.8 scores on a scale	Standard Error 2.36
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 49 (n=10,36)	14.5 scores on a scale	Standard Error 2.38
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 61 (n=4,17)	14.4 scores on a scale	Standard Error 3.53
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 97 (n=1,5)	11.1 scores on a scale	Standard Error 6.09
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 112 (n=1,5)	17.8 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 115 (n=1,4)	25.0 scores on a scale	Standard Error 5.32
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 118 (n=1,5)	17.8 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 133 (n=1,3)	14.8 scores on a scale	Standard Error 9.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 142 (n=0,2)	22.2 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 145 (n=0,1)	11.1 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Final Visit (n=158,160)	37.6 scores on a scale	Standard Error 2.31
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: BL (n=276,287)	15.7 scores on a scale	Standard Error 1.36
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 4 (n=235,250)	19.7 scores on a scale	Standard Error 1.46
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 10 (n=176,201)	16.4 scores on a scale	Standard Error 1.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 13 (n=121,183)	14.7 scores on a scale	Standard Error 1.55
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 16 (n=121,165)	14.5 scores on a scale	Standard Error 1.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 19 (n=114,143)	13.9 scores on a scale	Standard Error 1.59
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 22 (n=79,143)	12.2 scores on a scale	Standard Error 1.66
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 25 (n=64,124)	8.2 scores on a scale	Standard Error 1.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 31 (n=45,95)	8.8 scores on a scale	Standard Error 2.02
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 34 (n=37,87)	7.5 scores on a scale	Standard Error 1.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 37 (n=29,64)	6.8 scores on a scale	Standard Error 2.34
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 40 (n=24,55)	4.8 scores on a scale	Standard Error 1.87
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 43 (n=12,43)	1.2 scores on a scale	Standard Error 0.66
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 46 (n=14,42)	2.8 scores on a scale	Standard Error 1.12
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 49 (n=10,36)	0.9 scores on a scale	Standard Error 0.65
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 52 (n=8,30)	5.0 scores on a scale	Standard Error 2.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 64 (n=3,20)	4.2 scores on a scale	Standard Error 2.38
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 115 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 25 (n=64,124)	12.2 scores on a scale	Standard Error 1.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 97 (n=1,5)	3.3 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 112 (n=1,5)	3.3 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 121 (n=1,5)	3.3 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 142 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 25 (n=63,124)	9.4 scores on a scale	Standard Error 1.6
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 70 (n=3,14)	7.1 scores on a scale	Standard Error 5.16
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 76 (n=3,8)	8.3 scores on a scale	Standard Error 5.46
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 106 (n=1,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 109 (n=1,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 112 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 124 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 127 (n=1,3)	11.1 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 133 (n=1,3)	11.1 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: BL (n=276,285)	23.6 scores on a scale	Standard Error 1.71
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 4 (n=234,248)	23.3 scores on a scale	Standard Error 1.65
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 7 (n=181,219)	20.4 scores on a scale	Standard Error 1.69
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 13 (n=152,183)	18.9 scores on a scale	Standard Error 1.7
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 16 (n=120,164)	17.7 scores on a scale	Standard Error 1.88
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 19 (n=113,143)	20.0 scores on a scale	Standard Error 2.1
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 25 (n=64,124)	15.9 scores on a scale	Standard Error 2.14
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 28 (n=47,110)	13.3 scores on a scale	Standard Error 2.07
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 34 (n=37,87)	13.4 scores on a scale	Standard Error 2.07
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 46 (n=13,42)	9.5 scores on a scale	Standard Error 2.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 55 (n=6,24)	8.3 scores on a scale	Standard Error 3.01
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 61 (n=4,17)	7.8 scores on a scale	Standard Error 4.55
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 67 (n=4,17)	9.8 scores on a scale	Standard Error 4.75
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 109 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 121 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 133 (n=1,3)	11.1 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 136 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 139 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 142 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 49 (n=9,36)	6.5 scores on a scale	Standard Error 2.23
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 112 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 115 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 4 (n=235,247)	20.2 scores on a scale	Standard Error 1.76
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 13 (n=152,183)	15.8 scores on a scale	Standard Error 1.73
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 49 (n=10,36)	5.6 scores on a scale	Standard Error 2.1
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 76 (n=3,8)	4.2 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 106 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 112 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 115 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 124 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 133 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 142 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 31 (n=45,95)	4.9 scores on a scale	Standard Error 1.32
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 73 (n=3,12)	2.0 scores on a scale	Standard Error 1.96
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 97 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 124 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 136 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 142 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Final Visit (n=157,160)	10.0 scores on a scale	Standard Error 1.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: BL (n=274,286)	29.3 scores on a scale	Standard Error 1.89
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 4 (n=234,249)	27.7 scores on a scale	Standard Error 1.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 7 (n=178,220)	23.9 scores on a scale	Standard Error 1.96
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 16 (n=120,165)	24.4 scores on a scale	Standard Error 2.26
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 19 (n=113,143)	22.4 scores on a scale	Standard Error 2.49
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 22 (n=78,142)	24.9 scores on a scale	Standard Error 2.52
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 25 (n=63,124)	22.3 scores on a scale	Standard Error 2.34
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 28 (n=45,111)	21.6 scores on a scale	Standard Error 2.55
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 31 (n=45,94)	23.4 scores on a scale	Standard Error 2.89
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 34 (n=36,87)	24.5 scores on a scale	Standard Error 2.96
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 37 (n=29,64)	23.4 scores on a scale	Standard Error 3.38
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 40 (n=24,55)	23.6 scores on a scale	Standard Error 3.74
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 43 (n=12,43)	19.4 scores on a scale	Standard Error 3.72
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 46 (n=14,42)	18.3 scores on a scale	Standard Error 3.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 49 (n=10,35)	20.0 scores on a scale	Standard Error 4.14
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 52 (n=8,29)	20.7 scores on a scale	Standard Error 4.5
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 55 (n=6,24)	18.1 scores on a scale	Standard Error 5.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 58 (n=6,21)	22.2 scores on a scale	Standard Error 6.23
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 61 (n=4,17)	23.5 scores on a scale	Standard Error 6.86
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 64 (n=3,20)	16.7 scores on a scale	Standard Error 4.52
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 67 (n=4,17)	17.6 scores on a scale	Standard Error 5.05
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 70 (n=3,14)	19.0 scores on a scale	Standard Error 5.76
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 73 (n=3,12)	19.4 scores on a scale	Standard Error 4.95
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 76 (n=3,8)	25.0 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 79 (n=3,9)	25.9 scores on a scale	Standard Error 10.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 82 (n=2,6)	22.2 scores on a scale	Standard Error 7.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 85 (n=2,6)	16.7 scores on a scale	Standard Error 7.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 88 (n=2,6)	16.7 scores on a scale	Standard Error 7.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 91 (n=2,4)	25.0 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 94 (n=2,6)	16.7 scores on a scale	Standard Error 7.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 97 (n=1,5)	20.0 scores on a scale	Standard Error 8.16
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 100 (n=1,4)	16.7 scores on a scale	Standard Error 9.62
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 103 (n=1,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 106 (n=1,4)	16.7 scores on a scale	Standard Error 9.62
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 109 (n=1,4)	16.7 scores on a scale	Standard Error 9.62
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 118 (n=1,5)	13.3 scores on a scale	Standard Error 8.16
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 130 (n=0,3)	11.1 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 136 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 139 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 46 (n=13,42)	73.8 scores on a scale	Standard Error 3.18
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 49 (n=9,36)	76.6 scores on a scale	Standard Error 2.83
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: BL (n=274,287)	54.9 scores on a scale	Standard Error 1.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 4 (n=235,249)	60.9 scores on a scale	Standard Error 1.28
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 7 (n=180,220)	60.5 scores on a scale	Standard Error 1.36
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 10 (n=176,202)	61.9 scores on a scale	Standard Error 1.42
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 34 (n=36,87)	72.0 scores on a scale	Standard Error 2.18
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 37 (n=29,64)	70.6 scores on a scale	Standard Error 2.41
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 13 (n=152,182)	63.6 scores on a scale	Standard Error 1.47
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 16 (n=121,165)	61.9 scores on a scale	Standard Error 1.58
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 19 (n=114,143)	63.8 scores on a scale	Standard Error 1.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 22 (n=78,143)	64.9 scores on a scale	Standard Error 1.76
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 25 (n=64,124)	67.8 scores on a scale	Standard Error 2.02
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 40 (n=23,55)	70.6 scores on a scale	Standard Error 2.92
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 28 (n=47,111)	68.5 scores on a scale	Standard Error 2.08
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 31 (n=45,95)	70.0 scores on a scale	Standard Error 2.07
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 61 (n=4,17)	72.5 scores on a scale	Standard Error 5.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 64 (n=3,20)	70.0 scores on a scale	Standard Error 4.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 58 (n=5,21)	73.8 scores on a scale	Standard Error 4.68
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 67 (n=4,17)	72.5 scores on a scale	Standard Error 5.14
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 70 (n=3,14)	68.5 scores on a scale	Standard Error 5.61
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 73 (n=3,12)	68.1 scores on a scale	Standard Error 5.97
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 76 (n=3,8)	67.7 scores on a scale	Standard Error 8.97
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 79 (n=3,9)	69.4 scores on a scale	Standard Error 7.08
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 82 (n=2,5)	60.0 scores on a scale	Standard Error 10.34
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 85 (n=2,6)	79.2 scores on a scale	Standard Error 6.72
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 88 (n=2,6)	73.6 scores on a scale	Standard Error 5.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 91 (n=2,4)	79.2 scores on a scale	Standard Error 5.38
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 94 (n=2,6)	79.2 scores on a scale	Standard Error 7.98
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 100 (n=1,4)	85.4 scores on a scale	Standard Error 5.24
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 103 (n=1,3)	75.0 scores on a scale	Standard Error 4.81
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 106 (n=1,4)	77.1 scores on a scale	Standard Error 3.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 109 (n=1,4)	77.1 scores on a scale	Standard Error 3.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 115 (n=1,4)	72.9 scores on a scale	Standard Error 3.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 118 (n=1,5)	75.0 scores on a scale	Standard Error 3.73
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 121 (n=1,5)	75.0 scores on a scale	Standard Error 3.73
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 124 (n=1,5)	81.7 scores on a scale	Standard Error 5.53
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 127 (n=1,3)	72.2 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 130 (n=0,3)	72.2 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 133 (n=1,3)	72.2 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 136 (n=0,2)	66.7 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 139 (n=0,2)	66.7 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 142 (n=0,2)	66.7 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 145 (n=0,1)	66.7 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Final Visit (n=158,160)	53.1 scores on a scale	Standard Error 2.2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: BL (n=276,287)	79.6 scores on a scale	Standard Error 1.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 4 (n=235,250)	79.5 scores on a scale	Standard Error 1.2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 10 (n=174,201)	80.2 scores on a scale	Standard Error 1.22
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 13 (n=151,183)	80.5 scores on a scale	Standard Error 1.36
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 16 (n=121,165)	80.7 scores on a scale	Standard Error 1.37
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 19 (n=114,143)	81.5 scores on a scale	Standard Error 1.49
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 22 (n=79,143)	83.6 scores on a scale	Standard Error 1.38
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 25 (n=64,124)	84.8 scores on a scale	Standard Error 1.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 28 (n=47,110)	83.7 scores on a scale	Standard Error 1.6
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 31 (n=45,95)	85.4 scores on a scale	Standard Error 1.66
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 34 (n=37,87)	85.1 scores on a scale	Standard Error 1.89
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 37 (n=29,64)	85.8 scores on a scale	Standard Error 2.05
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 40 (n=24,55)	88.2 scores on a scale	Standard Error 1.88
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 43 (n=12,43)	89.9 scores on a scale	Standard Error 1.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 46 (n=14,42)	91.9 scores on a scale	Standard Error 1.53
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 49 (n=10,36)	92.0 scores on a scale	Standard Error 1.61
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 52 (n=8,30)	89.2 scores on a scale	Standard Error 2.71
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 55 (n=6,24)	93.1 scores on a scale	Standard Error 1.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 58 (n=6,21)	91.4 scores on a scale	Standard Error 2.88
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 61 (n=4,17)	91.0 scores on a scale	Standard Error 3.66
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 64 (n=3,20)	91.0 scores on a scale	Standard Error 3.36
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 67 (n=4,17)	93.3 scores on a scale	Standard Error 2.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 70 (n=3,14)	92.9 scores on a scale	Standard Error 3.73
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 73 (n=3,12)	91.1 scores on a scale	Standard Error 3.7
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 76 (n=3,8)	90.0 scores on a scale	Standard Error 5.49
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 79 (n=3,9)	92.6 scores on a scale	Standard Error 3.41
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 82 (n=2,6)	90.0 scores on a scale	Standard Error 6.38
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 85 (n=2,6)	95.6 scores on a scale	Standard Error 2.81
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 88 (n=2,6)	95.6 scores on a scale	Standard Error 2.22
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 91 (n=2,4)	98.3 scores on a scale	Standard Error 1.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 94 (n=2,6)	97.8 scores on a scale	Standard Error 2.22
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 97 (n=1,5)	97.3 scores on a scale	Standard Error 2.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 100 (n=1,4)	96.7 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 103 (n=1,4)	96.7 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 106 (n=1,4)	98.3 scores on a scale	Standard Error 1.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 109 (n=1,4)	95.0 scores on a scale	Standard Error 3.19
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 112 (n=1,5)	97.3 scores on a scale	Standard Error 2.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 115 (n=1,4)	93.3 scores on a scale	Standard Error 4.71
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 121 (n=1,5)	94.7 scores on a scale	Standard Error 3.89
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 124 (n=1,5)	96.0 scores on a scale	Standard Error 2.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 127 (n=1,3)	93.3 scores on a scale	Standard Error 3.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 130 (n=0,3)	93.3 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 133 (n=1,3)	95.6 scores on a scale	Standard Error 4.44
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 136 (n=0,2)	93.3 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 139 (n=0,2)	93.3 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 142 (n=0,2)	93.3 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Week 145 (n=0,1)	100.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Physical Functioning: Final Visit (n=158,161)	73.8 scores on a scale	Standard Error 2.19
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: BL (n=276,287)	73.9 scores on a scale	Standard Error 1.68
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 4 (n=234,250)	76.1 scores on a scale	Standard Error 1.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 7 (n=181,220)	73.3 scores on a scale	Standard Error 1.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 10 (n=176,202)	74.3 scores on a scale	Standard Error 1.87
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 13 (n=152,182)	75.1 scores on a scale	Standard Error 1.93
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 16 (n=121,165)	74.6 scores on a scale	Standard Error 1.98
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 19 (n=114,143)	75.8 scores on a scale	Standard Error 2.1
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 22 (n=79,142)	79.7 scores on a scale	Standard Error 1.93
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 25 (n=64,124)	82.4 scores on a scale	Standard Error 1.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 28 (n=47,110)	79.7 scores on a scale	Standard Error 2.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 34 (n=37,87)	82.2 scores on a scale	Standard Error 2.64
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 37 (n=29,64)	81.5 scores on a scale	Standard Error 2.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 40 (n=24,55)	82.1 scores on a scale	Standard Error 3.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 43 (n=12,43)	86.8 scores on a scale	Standard Error 2.63
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 46 (n=14,42)	86.5 scores on a scale	Standard Error 2.74
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 49 (n=10,36)	88.0 scores on a scale	Standard Error 2.94
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 52 (n=8,30)	84.4 scores on a scale	Standard Error 3.57
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 55 (n=6,24)	88.2 scores on a scale	Standard Error 3.68
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 58 (n=6,21)	89.7 scores on a scale	Standard Error 3.14
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 61 (n=4,17)	87.3 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 64 (n=3,20)	87.5 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 67 (n=4,17)	90.2 scores on a scale	Standard Error 3.52
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 70 (n=3,14)	86.9 scores on a scale	Standard Error 5
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 73 (n=3,12)	80.6 scores on a scale	Standard Error 5.36
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 79 (n=3,9)	81.5 scores on a scale	Standard Error 7.58
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 82 (n=2,6)	80.6 scores on a scale	Standard Error 10.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 85 (n=2,6)	91.7 scores on a scale	Standard Error 5.69
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 88 (n=2,6)	94.4 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 94 (n=2,6)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 97 (n=1,5)	90.0 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 100 (n=1,4)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 103 (n=1,4)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 106 (n=1,4)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 109 (n=1,4)	95.8 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 112 (n=1,5)	93.3 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 115 (n=1,4)	83.3 scores on a scale	Standard Error 9.62
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 118 (n=1,5)	86.7 scores on a scale	Standard Error 8.16
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 121 (n=1,5)	90.0 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 124 (n=1,5)	90.0 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 127 (n=1,3)	88.9 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 130 (n=0,3)	88.9 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 133 (n=1,3)	88.9 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 136 (n=0,2)	83.3 scores on a scale	Standard Error 16.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 139 (n=0,2)	83.3 scores on a scale	Standard Error 16.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 142 (n=0,2)	83.3 scores on a scale	Standard Error 16.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Week 145 (n=0,1)	100.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Role Functioning: Final Visit (n=158,161)	68.7 scores on a scale	Standard Error 2.51
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: BL (n=276,287)	73.1 scores on a scale	Standard Error 1.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 4 (n=235,250)	77.9 scores on a scale	Standard Error 1.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 7 (n=180,220)	80.2 scores on a scale	Standard Error 1.37
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 10 (n=176,202)	81.2 scores on a scale	Standard Error 1.31
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 13 (n=152,183)	80.5 scores on a scale	Standard Error 1.41
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 16 (n=121,165)	81.9 scores on a scale	Standard Error 1.49
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 19 (n=114,143)	82.4 scores on a scale	Standard Error 1.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 22 (n=79,143)	84.0 scores on a scale	Standard Error 1.53
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 25 (n=64,124)	84.8 scores on a scale	Standard Error 1.53
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 28 (n=47,111)	85.5 scores on a scale	Standard Error 1.54
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 31 (n=45,95)	85.7 scores on a scale	Standard Error 1.78
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 34 (n=37,87)	85.4 scores on a scale	Standard Error 1.86
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 37 (n=29,64)	86.3 scores on a scale	Standard Error 2.12
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 40 (n=24,55)	86.7 scores on a scale	Standard Error 2.23
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 43 (n=12,43)	87.8 scores on a scale	Standard Error 2.22
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 46 (n=14,42)	87.5 scores on a scale	Standard Error 2.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 49 (n=10,36)	91.4 scores on a scale	Standard Error 2.41
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 52 (n=8,29)	88.2 scores on a scale	Standard Error 3.16
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 55 (n=6,24)	88.5 scores on a scale	Standard Error 2.55
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 58 (n=6,21)	88.9 scores on a scale	Standard Error 3.22
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 61 (n=4,17)	90.7 scores on a scale	Standard Error 2.25
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 64 (n=3,20)	86.3 scores on a scale	Standard Error 3.59
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 67 (n=4,17)	89.2 scores on a scale	Standard Error 3.26
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 70 (n=3,14)	89.3 scores on a scale	Standard Error 4.41
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 73 (n=3,12)	82.9 scores on a scale	Standard Error 5.25
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 76 (n=3,8)	87.5 scores on a scale	Standard Error 6.86
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 79 (n=3,9)	84.3 scores on a scale	Standard Error 7.14
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 82 (n=2,6)	83.3 scores on a scale	Standard Error 13.61
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 85 (n=2,6)	91.7 scores on a scale	Standard Error 5.69
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 88 (n=2,6)	90.3 scores on a scale	Standard Error 3.98
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 91 (n=2,4)	95.8 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 94 (n=2,6)	88.9 scores on a scale	Standard Error 5.12
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 97 (n=1,5)	91.7 scores on a scale	Standard Error 5.27
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 100 (n=1,4)	87.5 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 103 (n=1,4)	87.5 scores on a scale	Standard Error 5.38
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 106 (n=1,4)	89.6 scores on a scale	Standard Error 3.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 109 (n=1,4)	91.7 scores on a scale	Standard Error 4.81
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 112 (n=1,5)	95.0 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 115 (n=1,4)	93.8 scores on a scale	Standard Error 3.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 118 (n=1,5)	90.0 scores on a scale	Standard Error 4.86
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 124 (n=1,5)	90.0 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 127 (n=1,3)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 130 (n=0,3)	88.9 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 133 (n=1,3)	91.7 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 136 (n=0,2)	95.8 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 142 (n=0,2)	95.8 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Week 145 (n=0,1)	100.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Emotional Functioning: Final Visit (n=158,161)	74.3 scores on a scale	Standard Error 2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: BL (n=276,287)	85.7 scores on a scale	Standard Error 1.2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 4 (n=235,250)	86.3 scores on a scale	Standard Error 1.14
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 7 (n=180,220)	86.5 scores on a scale	Standard Error 1.24
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 10 (n=176,202)	86.8 scores on a scale	Standard Error 1.22
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 13 (n=152,183)	85.7 scores on a scale	Standard Error 1.43
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 16 (n=121,165)	86.8 scores on a scale	Standard Error 1.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 19 (n=114,143)	87.6 scores on a scale	Standard Error 1.4
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 22 (n=79,143)	87.4 scores on a scale	Standard Error 1.53
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 25 (n=64,124)	87.4 scores on a scale	Standard Error 1.5
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 28 (n=47,111)	88.0 scores on a scale	Standard Error 1.54
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 31 (n=45,95)	90.0 scores on a scale	Standard Error 1.66
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 34 (n=37,87)	88.7 scores on a scale	Standard Error 1.69
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 37 (n=29,64)	91.4 scores on a scale	Standard Error 1.89
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 40 (n=24,55)	91.5 scores on a scale	Standard Error 1.93
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 43 (n=12,43)	91.5 scores on a scale	Standard Error 2.1
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 46 (n=14,42)	91.7 scores on a scale	Standard Error 2.14
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 49 (n=10,36)	92.6 scores on a scale	Standard Error 2.43
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 52 (n=8,29)	89.7 scores on a scale	Standard Error 3.35
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 55 (n=6,24)	91.0 scores on a scale	Standard Error 2.65
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 58 (n=6,21)	90.5 scores on a scale	Standard Error 3.37
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 61 (n=4,17)	91.2 scores on a scale	Standard Error 3.53
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 64 (n=3,20)	93.3 scores on a scale	Standard Error 3.29
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 67 (n=4,17)	91.2 scores on a scale	Standard Error 4.07
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 70 (n=3,14)	91.7 scores on a scale	Standard Error 4.19
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 73 (n=3,12)	83.3 scores on a scale	Standard Error 4.59
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 76 (n=3,8)	83.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 79 (n=3,9)	81.5 scores on a scale	Standard Error 7.58
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 82 (n=2,6)	88.9 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 85 (n=2,6)	91.7 scores on a scale	Standard Error 5.69
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 88 (n=2,6)	94.4 scores on a scale	Standard Error 3.51
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 91 (n=2,4)	95.8 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 94 (n=2,6)	94.4 scores on a scale	Standard Error 3.51
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 100 (n=1,4)	95.8 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 103 (n=1,4)	91.7 scores on a scale	Standard Error 4.81
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 106 (n=1,4)	95.8 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 112 (n=1,5)	93.3 scores on a scale	Standard Error 4.08
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 115 (n=1,4)	95.8 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 118 (n=1,5)	96.7 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 121 (n=1,5)	96.7 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 124 (n=1,5)	96.7 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 127 (n=1,3)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 130 (n=0,3)	88.9 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 133 (n=1,3)	94.4 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 136 (n=0,2)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 139 (n=0,2)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 142 (n=0,2)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Week 145 (n=0,1)	100.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Cognitive Functioning: Final Visit (n=158,161)	80.0 scores on a scale	Standard Error 2.05
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: BL (n=276,286)	72.0 scores on a scale	Standard Error 1.77
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 4 (n=235,250)	74.1 scores on a scale	Standard Error 1.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 7 (n=179,220)	75.1 scores on a scale	Standard Error 1.7
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 10 (n=176,202)	76.7 scores on a scale	Standard Error 1.65
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 13 (n=152,183)	76.3 scores on a scale	Standard Error 1.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 16 (n=180,165)	77.5 scores on a scale	Standard Error 1.88
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 19 (n=114,143)	79.5 scores on a scale	Standard Error 1.93
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 22 (n=79,143)	80.1 scores on a scale	Standard Error 2.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 28 (n=47,111)	80.2 scores on a scale	Standard Error 2.05
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 31 (n=45,95)	78.9 scores on a scale	Standard Error 2.42
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 34 (n=37,87)	80.7 scores on a scale	Standard Error 2.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 37 (n=29,64)	81.8 scores on a scale	Standard Error 2.59
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 40 (n=24,55)	82.7 scores on a scale	Standard Error 2.73
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 43 (n=12,43)	84.1 scores on a scale	Standard Error 2.77
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 46 (n=14,42)	86.9 scores on a scale	Standard Error 2.7
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 49 (n=10,36)	84.7 scores on a scale	Standard Error 3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 52 (n=8,29)	82.2 scores on a scale	Standard Error 3.87
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 58 (n=6,21)	87.3 scores on a scale	Standard Error 4.13
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 61 (n=4,17)	90.2 scores on a scale	Standard Error 3.52
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 64 (n=3,20)	85.8 scores on a scale	Standard Error 3.68
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 67 (n=4,17)	85.3 scores on a scale	Standard Error 4.71
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 70 (n=3,14)	86.9 scores on a scale	Standard Error 4.34
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 73 (n=3,12)	80.6 scores on a scale	Standard Error 5.36
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 76 (n=3,8)	81.3 scores on a scale	Standard Error 7.34
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Wek 82 (n=2,6)	80.6 scores on a scale	Standard Error 6.69
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 85 (n=2,6)	88.9 scores on a scale	Standard Error 7.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 88 (n=2,6)	88.9 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 91 (n=2,4)	91.7 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 94 (n=2,6)	91.7 scores on a scale	Standard Error 5.69
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 97 (n=1,5)	90.0 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 100 (n=1,4)	95.8 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 103 (n=1,4)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 106 (n=1,4)	91.7 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 112 (n=1,5)	96.7 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 115 (n=1,4)	95.8 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 118 (n=1,5)	96.7 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 121 (n=1,5)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 130 (n=0,3)	94.4 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 133 (n=1,3)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 136 (n=0,2)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 139 (n=0,2)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 142 (n=0,2)	100.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Week 145 (n=0,1)	100.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Social Functioning: Final Visit (n=158,161)	71.4 scores on a scale	Standard Error 2.39
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: BL (n=276,287)	34.2 scores on a scale	Standard Error 1.41
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 4 (n=235,250)	34.5 scores on a scale	Standard Error 1.34
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 7 (n=181,220)	34.1 scores on a scale	Standard Error 1.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 10 (n=176,201)	33.2 scores on a scale	Standard Error 1.5
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 13 (n=152,183)	33.7 scores on a scale	Standard Error 1.71
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 16 (n=121,165)	32.8 scores on a scale	Standard Error 1.76
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 22 (n=79,143)	26.7 scores on a scale	Standard Error 1.76
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 25 (n=64,124)	25.1 scores on a scale	Standard Error 1.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 31 (n=45,95)	22.2 scores on a scale	Standard Error 2.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 34 (n=37,87)	19.7 scores on a scale	Standard Error 2.28
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 37 (n=29,64)	19.8 scores on a scale	Standard Error 2.52
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 40 (n=24,55)	18.6 scores on a scale	Standard Error 2.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 43 (n=12,43)	17.1 scores on a scale	Standard Error 2.68
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 52 (n=8,30)	17.2 scores on a scale	Standard Error 3.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 55 (n=6,24)	14.4 scores on a scale	Standard Error 3.75
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 58 (n=6,21)	16.4 scores on a scale	Standard Error 3.22
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 64 (n=3,20)	17.2 scores on a scale	Standard Error 4.15
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 67 (n=4,17)	15.0 scores on a scale	Standard Error 4.04
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 70 (n=3,14)	16.7 scores on a scale	Standard Error 5.04
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 73 (n=3,12)	16.7 scores on a scale	Standard Error 5.38
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 76 (n=3,8)	18.1 scores on a scale	Standard Error 6.94
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 79 (n=3,9)	18.5 scores on a scale	Standard Error 7.64
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 82 (n=2,6)	29.6 scores on a scale	Standard Error 8.92
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 85 (n=2,6)	11.1 scores on a scale	Standard Error 5.74
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 88 (n=2,6)	9.3 scores on a scale	Standard Error 3.41
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 91 (n=2,4)	11.1 scores on a scale	Standard Error 7.86
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 94 (n=2,6)	7.4 scores on a scale	Standard Error 5.49
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 100 (n=1,4)	11.1 scores on a scale	Standard Error 7.86
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 103 (n=1,4)	19.4 scores on a scale	Standard Error 5.32
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 106 (n=1,4)	13.9 scores on a scale	Standard Error 6.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 109 (n=1,4)	16.7 scores on a scale	Standard Error 7.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 121 (n=1,5)	17.8 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 124 (n=1,5)	13.3 scores on a scale	Standard Error 6.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 127 (n=1,3)	14.8 scores on a scale	Standard Error 9.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 130 (n=0,3)	18.5 scores on a scale	Standard Error 7.41
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 136 (n=0,2)	22.2 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Fatigue: Week 139 (n=0,2)	22.2 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 28 (n=47,110)	6.5 scores on a scale	Standard Error 1.52
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 55 (n=6,24)	2.1 scores on a scale	Standard Error 1.15
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 58 (n=6,21)	3.2 scores on a scale	Standard Error 2.19
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 61 (n=4,17)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 67 (n=4,17)	2.9 scores on a scale	Standard Error 2.14
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 70 (n=3,14)	2.4 scores on a scale	Standard Error 2.38
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 73 (n=3,12)	1.4 scores on a scale	Standard Error 1.39
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 76 (n=3,8)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 97 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 100 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 103 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 106 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 109 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 112 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 118 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 121 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 124 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 127 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 130 (n=0,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 133 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 136 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 139 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 142 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Final Visit (n=158,161)	19.8 scores on a scale	Standard Error 2.36
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: BL (n=276,287)	25.1 scores on a scale	Standard Error 1.55
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 4 (n=235,250)	17.9 scores on a scale	Standard Error 1.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 7 (n=181,220)	16.1 scores on a scale	Standard Error 1.5
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 10 (n=176,202)	14.4 scores on a scale	Standard Error 1.42
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 13 (n=152,183)	13.3 scores on a scale	Standard Error 1.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 16 (n=121,165)	12.4 scores on a scale	Standard Error 1.54
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 19 (n=114,143)	12.8 scores on a scale	Standard Error 1.68
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 22 (n=79,143)	13.2 scores on a scale	Standard Error 1.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 28 (n=47,111)	12.0 scores on a scale	Standard Error 1.97
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 31 (n=45,95)	11.8 scores on a scale	Standard Error 2.22
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 34 (n=37,87)	11.3 scores on a scale	Standard Error 2.32
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 37 (n=29,64)	12.2 scores on a scale	Standard Error 2.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 40 (n=24,55)	10.3 scores on a scale	Standard Error 2.75
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 43 (n=12,43)	8.9 scores on a scale	Standard Error 2.44
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 46 (n=14,42)	6.7 scores on a scale	Standard Error 2.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 49 (n=10,36)	6.5 scores on a scale	Standard Error 2.23
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 52 (n=8,30)	10.0 scores on a scale	Standard Error 4.49
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 55 (n=6,24)	8.3 scores on a scale	Standard Error 4.01
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 58 (n=6,21)	7.1 scores on a scale	Standard Error 3.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 61 (n=4,17)	4.9 scores on a scale	Standard Error 3.43
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 64 (n=3,20)	6.7 scores on a scale	Standard Error 3.06
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 67 (n=4,17)	4.9 scores on a scale	Standard Error 2.77
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 70 (n=3,14)	4.8 scores on a scale	Standard Error 4.76
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 73 (n=3,12)	9.7 scores on a scale	Standard Error 5.97
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 76 (n=3,8)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 79 (n=3,9)	9.3 scores on a scale	Standard Error 7.41
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 82 (n=2,6)	2.8 scores on a scale	Standard Error 2.78
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 88 (n=2,6)	2.8 scores on a scale	Standard Error 2.78
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 91 (n=2,4)	4.2 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 100 (n=1,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 103 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 106 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 109 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 115 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 118 (n=1,5)	3.3 scores on a scale	Standard Error 3.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 124 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 127 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 130 (n=0,3)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 133 (n=1,3)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 136 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 139 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Pain: Final Visit (n=158,161)	25.4 scores on a scale	Standard Error 2.49
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: BL (n=274,281)	13.4 scores on a scale	Standard Error 1.23
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 4 (n=232,249)	11.8 scores on a scale	Standard Error 1.24
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 7 (n=181,217)	10.8 scores on a scale	Standard Error 1.21
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 10 (n=176,198)	11.3 scores on a scale	Standard Error 1.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 13 (n=151,182)	13.7 scores on a scale	Standard Error 1.74
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 16 (n=121,165)	13.5 scores on a scale	Standard Error 1.79
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 19 (n=113,143)	11.9 scores on a scale	Standard Error 1.7
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 22 (n=79,143)	12.1 scores on a scale	Standard Error 1.64
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 28 (n=47,110)	10.3 scores on a scale	Standard Error 1.76
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 31 (n=45,95)	9.1 scores on a scale	Standard Error 1.69
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 34 (n=36,87)	9.6 scores on a scale	Standard Error 2.1
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 37 (n=29,64)	10.4 scores on a scale	Standard Error 2.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 40 (n=24,55)	4.8 scores on a scale	Standard Error 1.6
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 43 (n=12,43)	6.2 scores on a scale	Standard Error 2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 46 (n=14,42)	5.6 scores on a scale	Standard Error 1.94
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 49 (n=10,36)	4.6 scores on a scale	Standard Error 1.95
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 52 (n=8,30)	5.6 scores on a scale	Standard Error 2.31
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 55 (n=6,24)	8.3 scores on a scale	Standard Error 3.01
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 58 (n=6,21)	6.3 scores on a scale	Standard Error 3.72
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 61 (n=4,17)	3.9 scores on a scale	Standard Error 2.68
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 64 (n=3,20)	8.3 scores on a scale	Standard Error 4.1
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 67 (n=4,17)	5.9 scores on a scale	Standard Error 4.27
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 73 (n=3,12)	8.3 scores on a scale	Standard Error 4.35
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 79 (n=3,9)	11.1 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 82 (n=2,6)	11.1 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 85 (n=2,6)	11.1 scores on a scale	Standard Error 7.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 88 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 94 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 97 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 100 (n=1,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 79 (n=3,9)	7.4 scores on a scale	Standard Error 4.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 82 (n=2,6)	16.7 scores on a scale	Standard Error 11.39
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 85 (n=180,6)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 88 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 91 (n=2,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 94 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 97 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 100 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 103 (n=1,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Nausea & Vomiting: Week 7 (n=181,220)	18.9 scores on a scale	Standard Error 1.63
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 115 (n=1,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 103 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 106 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 112 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 115 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 118 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 124 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 127 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 130 (n=0,3)	11.1 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Final Visit (n=157,160)	24.6 scores on a scale	Standard Error 2.28
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: BL (n=275,286)	33.8 scores on a scale	Standard Error 2.04
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 4 (n=235,250)	33.6 scores on a scale	Standard Error 2.01
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 7 (n=180,216)	31.3 scores on a scale	Standard Error 2.04
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 10 (n=176,201)	29.4 scores on a scale	Standard Error 2.08
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 13 (n=151,183)	28.4 scores on a scale	Standard Error 2.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 16 (n=121,165)	27.9 scores on a scale	Standard Error 2.23
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 19 (n=114,141)	25.1 scores on a scale	Standard Error 2.4
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 22 (n=79,143)	20.7 scores on a scale	Standard Error 2.19
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 25 (n=64,124)	16.7 scores on a scale	Standard Error 1.96
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 28 (n=47,109)	11.6 scores on a scale	Standard Error 1.96
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 31 (n=45,95)	13.0 scores on a scale	Standard Error 2.61
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 34 (n=37,87)	9.6 scores on a scale	Standard Error 2.24
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 37 (n=29,64)	10.9 scores on a scale	Standard Error 2.78
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 40 (n=24,55)	9.7 scores on a scale	Standard Error 2.69
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 43 (n=12,43)	7.0 scores on a scale	Standard Error 2.37
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 46 (n=14,42)	5.6 scores on a scale	Standard Error 2.25
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 52 (n=8,30)	10.0 scores on a scale	Standard Error 3.96
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 55 (n=6,24)	10.0 scores on a scale	Standard Error 3.96
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 58 (n=6,21)	4.8 scores on a scale	Standard Error 2.61
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 61 (n=4,17)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 64 (n=3,20)	8.3 scores on a scale	Standard Error 4.1
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 67 (n=4,17)	5.9 scores on a scale	Standard Error 3.18
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 70 (n=3,14)	7.1 scores on a scale	Standard Error 5.16
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 73 (n=3,12)	5.6 scores on a scale	Standard Error 3.75
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 76 (n=3,8)	4.2 scores on a scale	Standard Error 4.17
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 82 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 85 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 88 (n=2,6)	11.1 scores on a scale	Standard Error 7.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 94 (n=2,6)	5.6 scores on a scale	Standard Error 5.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 97 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 100 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 103 (n=1,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 106 (n=1,4)	8.3 scores on a scale	Standard Error 8.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 109 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 118 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 121 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 124 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 127 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 130 (n=0,3)	11.1 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 133 (n=1,3)	11.1 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 136 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 139 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 142 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Appetite Loss: Week Final Visit (n=156,161)	33.5 scores on a scale	Standard Error 2.76
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: BL (n=276,285)	21.5 scores on a scale	Standard Error 1.69
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 7 (n=179,220)	17.6 scores on a scale	Standard Error 1.79
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 10 (n=175,203)	15.1 scores on a scale	Standard Error 1.68
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 16 (n=121,165)	15.4 scores on a scale	Standard Error 1.87
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 19 (n=114,143)	14.5 scores on a scale	Standard Error 1.94
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 22 (n=78,143)	10.0 scores on a scale	Standard Error 1.62
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 25 (n=64,124)	10.2 scores on a scale	Standard Error 1.71
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 28 (n=47,111)	9.6 scores on a scale	Standard Error 1.93
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 31 (n=45,95)	6.3 scores on a scale	Standard Error 1.68
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 34 (n=37,86)	4.7 scores on a scale	Standard Error 1.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 37 (n=29,64)	10.4 scores on a scale	Standard Error 2.96
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 40 (n=24,55)	7.9 scores on a scale	Standard Error 2.28
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 43 (n=12,43)	7.0 scores on a scale	Standard Error 2.37
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 46 (n=14,42)	7.1 scores on a scale	Standard Error 2.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 52 (n=8,29)	10.3 scores on a scale	Standard Error 4.09
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 55 (n=6,24)	6.9 scores on a scale	Standard Error 4.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 58 (n=6,21)	6.3 scores on a scale	Standard Error 3.72
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 61 (n=4,17)	5.9 scores on a scale	Standard Error 4.27
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 64 (n=3,20)	5.0 scores on a scale	Standard Error 3.65
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 67 (n=4,17)	5.9 scores on a scale	Standard Error 4.27
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 70 (n=3,14)	4.8 scores on a scale	Standard Error 4.76
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 73 (n=3,12)	11.1 scores on a scale	Standard Error 6.27
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 79 (n=3,9)	3.7 scores on a scale	Standard Error 3.7
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 82 (n=2,6)	16.7 scores on a scale	Standard Error 16.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 97 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 100 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 103 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 109 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 118 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 121 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 127 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 130 (n=0,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 136 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 139 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Constipation: Final Visit (n=158,160)	20.0 scores on a scale	Standard Error 2.16
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: BL (n=276,283)	10.7 scores on a scale	Standard Error 1.14
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 4 (n=234,246)	12.2 scores on a scale	Standard Error 1.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 7 (n=180,220)	14.2 scores on a scale	Standard Error 1.65
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 10 (n=174,202)	11.9 scores on a scale	Standard Error 1.55
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 13 (n=152,183)	12.0 scores on a scale	Standard Error 1.66
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 16 (n=120,165)	12.9 scores on a scale	Standard Error 1.61
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 19 (n=114,143)	10.3 scores on a scale	Standard Error 1.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 22 (n=78,143)	9.6 scores on a scale	Standard Error 1.43
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 25 (n=64,124)	6.2 scores on a scale	Standard Error 1.23
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 28 (n=47,111)	4.8 scores on a scale	Standard Error 1.2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 34 (n=37,87)	5.7 scores on a scale	Standard Error 1.56
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 37 (n=29,64)	4.2 scores on a scale	Standard Error 1.39
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 40 (n=24,55)	3.0 scores on a scale	Standard Error 1.79
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 43 (n=12,42)	2.4 scores on a scale	Standard Error 1.76
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 46 (n=14,42)	1.6 scores on a scale	Standard Error 1.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 49 (n=10,36)	3.7 scores on a scale	Standard Error 1.77
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 52 (n=8,29)	2.3 scores on a scale	Standard Error 1.6
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 55 (n=6,24)	4.2 scores on a scale	Standard Error 2.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 58 (n=6,21)	4.8 scores on a scale	Standard Error 2.61
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 61 (n=4,17)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 64 (n=3,20)	3.3 scores on a scale	Standard Error 2.29
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 67 (n=4,17)	2.0 scores on a scale	Standard Error 1.96
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 70 (n=3,14)	3.3 scores on a scale	Standard Error 2.29
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 76 (n=3,8)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 79 (n=3,9)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 82 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 85 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 88 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 91 (n=2,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 94 (n=2,6)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 100 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 103 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 106 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 109 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 112 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 115 (n=1,4)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 118 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 121 (n=1,5)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 127 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 130 (n=0,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 133 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Diarrhoea: Week 139 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 10 (n=175,202)	23.3 scores on a scale	Standard Error 2.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 13 (n=151,181)	22.7 scores on a scale	Standard Error 2.08
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 118 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 121 (n=1,5)	6.7 scores on a scale	Standard Error 6.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 130 (n=0,3)	11.1 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 136 (n=0,2)	16.7 scores on a scale	Standard Error 16.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 139 (n=0,2)	16.7 scores on a scale	Standard Error 16.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 142 (n=0,2)	16.7 scores on a scale	Standard Error 16.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Week 145 (n=0,1)	33.3 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Dyspnoea: Final Visit (n=157,160)	18.3 scores on a scale	Standard Error 2.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 10 (n=175,200)	18.0 scores on a scale	Standard Error 1.63
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 22 (n=79,143)	17.0 scores on a scale	Standard Error 2.24
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 31 (n=45,94)	14.9 scores on a scale	Standard Error 2.34
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 37 (n=29,63)	11.1 scores on a scale	Standard Error 2.26
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 40 (n=24,55)	10.3 scores on a scale	Standard Error 2.58
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 43 (n=12,43)	9.3 scores on a scale	Standard Error 2.79
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 49 (n=10,36)	7.4 scores on a scale	Standard Error 2.69
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 52 (n=8,30)	7.8 scores on a scale	Standard Error 3.07
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 58 (n=6,21)	9.5 scores on a scale	Standard Error 4.08
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 64 (n=3,20)	10.0 scores on a scale	Standard Error 4.9
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 70 (n=3,14)	9.5 scores on a scale	Standard Error 5.45
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 73 (n=3,12)	11.1 scores on a scale	Standard Error 6.27
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Insomnia: Week 76 (n=3,8)	8.3 scores on a scale	Standard Error 5.46
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 112 (n=1,5)	13.3 scores on a scale	Standard Error 8.16
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 115 (n=1,4)	16.7 scores on a scale	Standard Error 9.62
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 121 (n=1,5)	13.3 scores on a scale	Standard Error 8.16
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 124 (n=1,5)	13.3 scores on a scale	Standard Error 8.16
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 127 (n=1,3)	11.1 scores on a scale	Standard Error 11.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 133 (n=1,3)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 142 (n=0,2)	0.0 scores on a scale	Standard Error 0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Financial Difficulties: Week 145 (n=0,1)	0.0 scores on a scale	—
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores	Global Health Status: Week 43 (n=12,43)	73.6 scores on a scale	Standard Error 3.23

Secondary

Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)

The participant assessed their pain on a 0 to 100 millimeter (mm) horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as no pain and the right-hand extreme equals 100 mm as unbearable pain. A negative change indicated improvement.

Time frame: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS; n = number of participants assessed for a specific parameter at a given visit.

Arm	Measure	Group	Value (MEAN)	Dispersion
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 46 (n=14,41)	16.1 mm	Standard Error 6.11
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 58 (n=6,20)	4.7 mm	Standard Error 2.2
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	BL (n=275,284)	21.1 mm	Standard Error 1.42
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 61 (n=4,17)	5.3 mm	Standard Error 3.04
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 4 (n=234,249)	14.6 mm	Standard Error 1.17
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 64 (n=3,20)	2.0 mm	Standard Error 1
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 7 (n=181,219)	11.1 mm	Standard Error 1.15
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 70 (n=3,13)	1.3 mm	Standard Error 1.33
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 67 (n=4,17)	1.5 mm	Standard Error 0.96
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 73 (n=3,10)	1.0 mm	Standard Error 0.58
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 13 (n=152,181)	11.3 mm	Standard Error 1.37
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 76 (n=3,8)	1.7 mm	Standard Error 0.88
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 91 (n=2,4)	0.5 mm	Standard Error 0.5
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 79 (n=3,9)	1.0 mm	Standard Error 0.58
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 22 (n=79,141)	13.3 mm	Standard Error 2.2
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 82 (n=2,6)	0.0 mm	Standard Error 0
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 19 (n=114,142)	15.4 mm	Standard Error 1.92
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 85 (n=2,6)	1.0 mm	Standard Error 1
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 25 (n=64,124)	12.7 mm	Standard Error 2.39
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 88 (n=2,6)	0.5 mm	Standard Error 0.5
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 94 (n=2,6)	0.5 mm	Standard Error 0.5
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 97 (n=1,5)	0.0 mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 31 (n=45,95)	8.7 mm	Standard Error 2.11
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 100 (n=1,4)	0.0 mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 10 (n=174, 202)	14.5 mm	Standard Error 1.46
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 103 (n=1,4)	0.0 mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 34 (n=37,86)	9.4 mm	Standard Error 2.9
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 106 (n=1,4)	0.0 mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 28 (n=47,111)	8.6 mm	Standard Error 1.85
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 109 (n=1,4)	0.0 mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 112 (n=1,5)	0.0 mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 37 (n=29,64)	15.5 mm	Standard Error 4.08
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 115 (n=1,4)	0.0 mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 118 (n=1,5)	0.0 mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 40 (n=24,54)	16.4 mm	Standard Error 4.2
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 121 (n=1,5)	0.0 mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 124 (n=1,4)	0.0 mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 43 (n=12,43)	12.6 mm	Standard Error 5.04
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 127 (n=1,3)	0.0 mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 49 (n=10,36)	7.2 mm	Standard Error 3.71
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 130 (n=0,3)	NA mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 133 (n=1,3)	0.0 mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 136 (n=0,2)	NA mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 139 (n=0,2)	NA mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 52 (n=8,30)	5.8 mm	Standard Error 3.43
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 142 (n=0,2)	NA mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 16 (n=121,165)	14.0 mm	Standard Error 1.77
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 145 (n=0,1)	NA mm	—
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 55 (n=6,24)	2.3 mm	Standard Error 1.2
Fluoropyrimidine/Cisplatin (FP)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Final visit/withdrawal (n=157,161)	23.8 mm	Standard Error 1.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 76 (n=3,8)	12.9 mm	Standard Error 11.12
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 10 (n=174, 202)	12.9 mm	Standard Error 1.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 13 (n=152,181)	12.2 mm	Standard Error 1.35
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 16 (n=121,165)	12.8 mm	Standard Error 1.53
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 25 (n=64,124)	11.0 mm	Standard Error 1.5
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 43 (n=12,43)	7.2 mm	Standard Error 2.15
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 64 (n=3,20)	6.8 mm	Standard Error 3.14
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 91 (n=2,4)	7.5 mm	Standard Error 6.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 94 (n=2,6)	5.8 mm	Standard Error 5.83
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 109 (n=1,4)	7.3 mm	Standard Error 7.25
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 130 (n=0,3)	5.7 mm	Standard Error 5.67
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 136 (n=0,2)	6.0 mm	Standard Error 6
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Final visit/withdrawal (n=157,161)	21.9 mm	Standard Error 2.18
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 4 (n=234,249)	13.3 mm	Standard Error 1.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 7 (n=181,219)	13.8 mm	Standard Error 1.31
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 19 (n=114,142)	12.0 mm	Standard Error 1.43
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 22 (n=79,141)	15.1 mm	Standard Error 1.81
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 28 (n=47,111)	12.3 mm	Standard Error 1.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 31 (n=45,95)	12.5 mm	Standard Error 1.92
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 34 (n=37,86)	10.7 mm	Standard Error 1.79
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 37 (n=29,64)	10.9 mm	Standard Error 2.22
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 40 (n=24,54)	8.8 mm	Standard Error 1.99
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 46 (n=14,41)	7.4 mm	Standard Error 2.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 49 (n=10,36)	6.5 mm	Standard Error 2.09
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 52 (n=8,30)	6.9 mm	Standard Error 2.75
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 55 (n=6,24)	3.3 mm	Standard Error 1.48
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 58 (n=6,20)	3.8 mm	Standard Error 1.91
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 61 (n=4,17)	7.2 mm	Standard Error 5.03
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 67 (n=4,17)	8.9 mm	Standard Error 5.04
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 70 (n=3,13)	1.3 mm	Standard Error 1.15
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 73 (n=3,10)	16.5 mm	Standard Error 8.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	BL (n=275,284)	17.9 mm	Standard Error 1.25
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 79 (n=3,9)	5.9 mm	Standard Error 3.89
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 82 (n=2,6)	4.8 mm	Standard Error 4.83
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 85 (n=2,6)	6.3 mm	Standard Error 6.14
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 88 (n=2,6)	5.7 mm	Standard Error 5.47
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 97 (n=1,5)	0.2 mm	Standard Error 0.2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 100 (n=1,4)	0.3 mm	Standard Error 0.25
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 103 (n=1,4)	6.5 mm	Standard Error 5.85
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 106 (n=1,4)	7.8 mm	Standard Error 6.79
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 112 (n=1,5)	4.2 mm	Standard Error 3.5
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 115 (n=1,4)	5.8 mm	Standard Error 5.11
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 118 (n=1,5)	3.8 mm	Standard Error 3.32
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 121 (n=1,5)	3.2 mm	Standard Error 3.2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 124 (n=1,4)	4.5 mm	Standard Error 3.84
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 127 (n=1,3)	6.3 mm	Standard Error 6.33
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 133 (n=1,3)	5.0 mm	Standard Error 5
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 139 (n=0,2)	8.0 mm	Standard Error 8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 142 (n=0,2)	7.5 mm	Standard Error 7.5
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)	Week 145 (n=0,1)	15.0 mm	—

Secondary

Percentage of Participants With a Change in Analgesic Medication During the Study

Analgesic medications were recorded throughout the study until disease progression.

Time frame: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS

Arm	Measure	Group	Value (NUMBER)
Fluoropyrimidine/Cisplatin (FP)	Percentage of Participants With a Change in Analgesic Medication During the Study	Discontinued at least 1 medication	5.9 percentage of participants
Fluoropyrimidine/Cisplatin (FP)	Percentage of Participants With a Change in Analgesic Medication During the Study	No change in any medication	5.5 percentage of participants
Fluoropyrimidine/Cisplatin (FP)	Percentage of Participants With a Change in Analgesic Medication During the Study	Decreased dose of at least 1 medication	0.3 percentage of participants
Fluoropyrimidine/Cisplatin (FP)	Percentage of Participants With a Change in Analgesic Medication During the Study	Increased dose or added at least 1 medication	17.2 percentage of participants
Fluoropyrimidine/Cisplatin (FP)	Percentage of Participants With a Change in Analgesic Medication During the Study	Taking any analgesic medication	29.0 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Percentage of Participants With a Change in Analgesic Medication During the Study	Increased dose or added at least 1 medication	20.1 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Percentage of Participants With a Change in Analgesic Medication During the Study	Taking any analgesic medication	29.3 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Percentage of Participants With a Change in Analgesic Medication During the Study	Discontinued at least 1 medication	1.7 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Percentage of Participants With a Change in Analgesic Medication During the Study	Decreased dose of at least 1 medication	0.3 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Percentage of Participants With a Change in Analgesic Medication During the Study	No change in any medication	7.1 percentage of participants

Secondary

Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight

Change in body weight was categorized as an increase of greater than (\>)5 percent (%), no change (plus or minus \[±\]5%), decrease of \>5-10%, or a decrease of \>10% from BL to the end of study. Time windows were applied in order to assign visits to weight measurements, and the lowest post-screening value recorded was used for the analysis. The percentage change in weight from screening was summarized over time.

Time frame: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS. 273 and 283 participants were analyzed in the Fluoropyrimidine, Cisplatin and Trastuzumab, Fluoropyrimidine, Cisplatin groups, respectively.

Arm	Measure	Group	Value (NUMBER)
Fluoropyrimidine/Cisplatin (FP)	Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight	Increase >5%	1.5 percentage of participants
Fluoropyrimidine/Cisplatin (FP)	Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight	Decrease >5-10%	28.2 percentage of participants
Fluoropyrimidine/Cisplatin (FP)	Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight	Decrease >10%	18.7 percentage of participants
Fluoropyrimidine/Cisplatin (FP)	Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight	No change (±5%)	51.6 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight	Decrease >10%	21.2 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight	Increase >5%	1.1 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight	No change (±5%)	50.5 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight	Decrease >5-10%	27.2 percentage of participants

Secondary

Percentage of Participants With Clinical Benefit

Clinical benefit was defined as stable disease (SD), CR, or PR for 6 weeks or longer as determined by RECIST. For TLs, SD was defined as neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD, taking as a reference the smallest SLD recorded since treatment had started. For NTLs, SD was defined as a persistence of one or more NTLs and/or maintenance of tumor marker levels above the normal limits.

Time frame: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS

Arm	Measure	Value (NUMBER)
Fluoropyrimidine/Cisplatin (FP)	Percentage of Participants With Clinical Benefit	69.3 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Percentage of Participants With Clinical Benefit	78.9 percentage of participants

p-value: 0.008195% CI: [2.4, 16.9]Chi-squared

95% CI: [1.14, 2.41]

Secondary

Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors (RECIST)

For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels.

Time frame: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS

Arm	Measure	Value (NUMBER)
Fluoropyrimidine/Cisplatin (FP)	Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors (RECIST)	34.5 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors (RECIST)	47.3 percentage of participants

p-value: 0.001795% CI: [4.7, 20.9]Chi-squared

Secondary

Progression-Free Survival (PFS) - Percentage of Participants With an Event

PFS was defined as the time from the date of randomization to the date of the first documentation of progressive disease (PD) or date of death, whichever occurs first. For target lesions (TL), PD was defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD) of TLs, taking as a reference the smallest SLD recorded since the treatment started, or the appearance of one or more lesions. For non-target lesions (NTL), PD was defined as an unequivocal progression of existing NTLs. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.

Time frame: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS

Arm	Measure	Value (NUMBER)
Fluoropyrimidine/Cisplatin (FP)	Progression-Free Survival (PFS) - Percentage of Participants With an Event	81.0 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Progression-Free Survival (PFS) - Percentage of Participants With an Event	76.9 percentage of participants

Secondary

Progression-Free Survival - Time to Event

The median time, in months, from the date of randomization to the date of a PFS event. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.

Time frame: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS

Arm	Measure	Value (MEDIAN)
Fluoropyrimidine/Cisplatin (FP)	Progression-Free Survival - Time to Event	5.5 months
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Progression-Free Survival - Time to Event	6.7 months

p-value: 0.000295% CI: [0.59, 0.85]Log Rank

Secondary

Steady State Trastuzumab Area Under the Concentration (AUC)

Individual steady state predicted exposure, as assessed by median AUC (measured as mg multiplied by \[\*\] day per liter \[L\]) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion. Individual steady state AUC was calculated using all available PK samples from all timepoints.

Time frame: Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106

Population: Pharmacokinetic (PK) population: all participants with at least 1 measurement of trastuzumab serum concentration associated with a documented trastuzumab dosing history.

Arm	Measure	Value (MEDIAN)
Fluoropyrimidine/Cisplatin (FP)	Steady State Trastuzumab Area Under the Concentration (AUC)	1030 mg*day/L

Secondary

Time to Progression - Time to Event

The median time, in months, from the date of randomized to the date of a TTP event. Participants were censored at the last date of tumor assessment, the last date in the study drug log, or the last date of follow-up.

Time frame: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS

Arm	Measure	Value (MEDIAN)
Fluoropyrimidine/Cisplatin (FP)	Time to Progression - Time to Event	5.6 months
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Time to Progression - Time to Event	7.1 months

p-value: 0.000395% CI: [0.58, 0.85]Log Rank

Secondary

Time to Progression (TTP) - Percentage of Participants With an Event

TTP was defined as the time from the date of randomization and the date of the first occurrence of PD. Participants were censored at the last date of tumor assessment, the last date in the study drug log, or the last date of follow-up.

Time frame: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Population: FAS

Arm	Measure	Value (NUMBER)
Fluoropyrimidine/Cisplatin (FP)	Time to Progression (TTP) - Percentage of Participants With an Event	74.1 percentage of participants
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)	Time to Progression (TTP) - Percentage of Participants With an Event	70.7 percentage of participants

Secondary

Trastuzumab Maximum Serum Concentration (Cmax)

Median Cmax (measured as mg/L) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion.

Time frame: Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106

Population: PK Population

Arm	Measure	Value (MEDIAN)
Fluoropyrimidine/Cisplatin (FP)	Trastuzumab Maximum Serum Concentration (Cmax)	128 mg/L

Secondary

Trastuzumab Minimum Serum Concentration (Cmin)

Median Cmin (measured as milligrams per liter \[mg/L\]) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion.

Time frame: Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106

Population: PK Population

Arm	Measure	Value (MEDIAN)
Fluoropyrimidine/Cisplatin (FP)	Trastuzumab Minimum Serum Concentration (Cmin)	23.0 mg/L

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026

ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer

Conditions

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Overall Survival (OS) - Percentage of Participants With an Event

Overall Survival - Time to Event

Body Weight (Kilograms [kg]) at BL

Duration of Response

Duration of Response - Percentage of Participants With an Event

EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores

European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores

Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)

Percentage of Participants With a Change in Analgesic Medication During the Study

Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight

Percentage of Participants With Clinical Benefit

Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors (RECIST)

Progression-Free Survival (PFS) - Percentage of Participants With an Event

Progression-Free Survival - Time to Event

Steady State Trastuzumab Area Under the Concentration (AUC)

Time to Progression - Time to Event

Time to Progression (TTP) - Percentage of Participants With an Event

Trastuzumab Maximum Serum Concentration (Cmax)

Trastuzumab Minimum Serum Concentration (Cmin)